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Risperidone is an ‘atypical’ antipsychotic and is approved by the USFDA mainly 
for the treatment of schizophrenia and symptoms of bipolar disorder. Risperidone (an SDA 
or serotonin-dopamine antagonist) has ∼20-fold higher affinity at 5-HT2A receptors over 
dopamine D2 receptors, which makes it more efficacious against the negative symptoms of 
schizophrenia and less liable to causing extrapyramidal side effects than ‘typical’ 
antipsychotics.  
The major goal of the current investigation was to study the structure of risperidone 
and to identify the minimum structural features required for 5-HT2A receptor affinity that 
retain antagonist action. The structure of risperidone was systematically deconstructed, and 
    
 
functional activity studies using calcium imaging in HEK293 cells and a two-electrode 
voltage clamp (TEVC) assay in a Xenopus laevis heterologous system were coupled with 
radioligand binding affinity studies to achieve this goal. The biological studies showed that 
the entire structure of risperidone was not required for activity or affinity at the receptor, as 
6-fluoro-[3-(1-methylpiperidin-4-yl)]benz[d]isoxazole was comparable to risperidone in 
both affinity and activity.  
Next, the structure of risperidone was elaborated to determine the importance of its 
left and right “halves” in its actions. The left and the right halves of risperidone were 
substituted with those of another antagonist, ketanserin, to give structural hybrids.  
Biological studies suggested that the right half of risperidone [i.e., the 6-fluoro-(3-
piperidin-4-yl)benz[d]isoxazole moiety] might be important for affinity. 
In order to assess how the biologically-active compounds interact at the receptor, 
homology models of the human 5-HT2A receptor were developed, and docking and 
Hydropathic INTeraction studies were conducted. Risperidone seemed to form a bifurcated 
hydrogen bond with S159 (TM3), which ketanserin was unable to form. This interaction 
might account for high binding affinity at the receptor as it is common to both, risperidone 
and 3-[2-(4-(6-fluorobenz[d]isoxazol-3-yl)piperidin-1-yl)ethyl]-2,4-(1H,3H)quinazolinedi-                                   
one. 
With the data currently in hand, we can conclude that the entire structure of 
risperidone is not required for activity or affinity, and that the right “half” (i.e. the 
benzisoxazolyl portion) of risperidone might be influencing activity and affinity at 5-HT2A 
receptors.   
    
 1 
 
 
CHAPTER I: INTRODUCTION 
 
 
 
 
 Schizophrenia is a mental disorder currently affecting about 1% of the world’s 
population, and is a leading cause of disability, unemployment and suicide in developed 
countries.1 Compared to depression, mania and other psychiatric disorders, the documented 
origins of schizophrenia are fairly recent (early nineteenth century), although earlier the 
disorder might have been referred to in general as ‘madness’.2  
 
A striking property of schizophrenia that distinguishes it from other psychiatric illnesses is 
the apparent loss of touch with reality. This manifests in the form of paranoid delusions 
and hallucinations (positive symptoms).3 Before the advent of antipsychotics, large mental 
institutions were common and patients were locked up – often lifelong, and their 
symptoms were suppressed by inducing insulin coma or by the surgical excision of certain 
sections of the brain.4 These techniques, though temporarily effective in calming patients, 
had disastrous repercussions in the long run.  
 
The discovery of chlorpromazine and the subsequent development of the typical 
antipsychotics was a revolution in psychiatry as they alleviated the positive symptoms of 
the disorder.5 These typical antipsychotics were dopamine D2 receptor antagonists and 
although effective against the positive symptoms, they were ineffective against the apathy 
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and anhedonia (negative symptoms) and cognitive deficits associated with the disorder and 
their predominantly dopaminergic activity led to extrapyramidal side effects such as 
tremors and rigidity.5  
 
The importance of the serotonergic system was realized after certain 5-HT2A receptor 
antagonists such as ritanserin and spiperone exhibited activity against the negative 
symptoms of schizophrenia.6 It was established later that an optimum ratio of D2/5-HT2A 
receptor affinity (Meltzer’s ratio) was necessary for activity against the positive, negative 
and cognitive symptoms; and a higher Meltzer’s ratio correlated with a lower risk of 
causing extrapyramidal side effects.7 This led to the development of atypical 
antipsychotics, which are dual serotonin-dopamine antagonists such as risperidone.  
 
Risperidone had certain structural features that distinguished it from structurally related 
predecessors such as ketanserin and from its atypical contemporaries such as clozapine. Its 
high Meltzer’s ratio of ∼20 led to an ideal D2/5-HT2A receptor affinity profile such that 
when about 50% of the D2 receptors are occupied, nearly all 5-HT2A receptors are occupied 
and this was sufficient for its antipsychotic activity. In addition, it has a gradual occupancy 
at D2 receptors, combined with a rapid dissociation rate.8 Thus, risperidone seemed to 
possess the perfect features to combat the symptoms of schizophrenia without causing 
extrapyramidal side effects.  
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Risperidone has recently demonstrated the ability to crosstalk at the 5-HT2A-mGlu2 
receptor heteromer complex, which is a potential novel target for schizophrenia.9 The 
purpose of the current investigation is to determine the structural features of risperidone 
conferring it with its antagonist activity at 5-HT2A receptors, with the long-term goal of 
synthesizing a bivalent ligand capable of targeting the 5-HT2A-mGlu2 receptor heteromer.
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CHAPTER II: BACKGROUND 
 
 
 
 
A. MENTAL HEALTH AND THE WORLD 
1. Current status of mental health in the world:  
After years of hiding under the garb of ignorance and superstitions, psychiatry finally came 
to the forefront of health science after Delay and Deniker administered chlorpromazine 
(thorazine®) (CPZ) (1)  (Figure 1) to patients at the St. Anne’s hospital in Paris in 1952.4 
Psychiatry has come a long way since the days of moral therapy and barbaric methods such 
as insulin coma, convulsive therapy, and pre-frontal lobotomy.4 The National Mental 
Health Act of 1946 and the establishment of the National Institute of Mental Health 
(NIMH) called for government-sponsored research towards mental illness.10 There has 
been progress in every field of psychiatry including development of antipsychotic agents 
(Figure 1) to combat schizophrenia-like symptoms and antianxiety drugs (initially referred 
to as minor tranquilizers), to antidepressants (initially called psychic energizers).4,11 
 
Research of over three quarters of a century has generated a wealth of research articles; 
blog posts and the media have helped propel mental health into public scrutiny, and 
communities all over the world are gradually accepting the importance of mental well-
being.10  
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Figure 1. Examples of antipsychotic agents currently on the market.12  
 
The World Health Organization (WHO) has charted the ‘Comprehensive Mental Health 
Action Plan 2013-2020’ with the aim of ensuring the worldwide availability of mental 
health resources, and released the WHO Mental Health Atlas starting from 2001 and 
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updated in 2005, 2011 and 2014, that measures the progress of member states in realizing 
the goals of the plan. According to the WHO Mental Health Atlas 2014, out of the 131 
responders of the 194 WHO members, about 68% had a mental health policy or a plan for 
mental health and 51% have a self-contained mental health law.13 
 
As per the report there is a huge gap in the conditions existing among the countries based 
on per capita income. As regards availability of resources, there is a huge gap in low- and 
high-income countries. The situation is as dire as 1 mental health worker per 100,000 
population in low-income countries to more than 50 per 100,000 population in high-
income countries.13,14 This disparity seems to continue even in sources of funding for 
treatment of mental health conditions and the median mental health expenditure per capita. 
Government is the main source of funding in 79% of the countries; however, out-of-pocket 
is also the main source of funding for 18% of the countries, suggesting either a dearth in 
funds or its unequal distribution.13 The median mental health expenditure per capita is as 
low as $1.53 and $1.96 for low- and middle-income countries, respectively, and $58.73 for 
high-income countries.13,14  
 
Over the years there has been a greater focus on community-based mental health services 
(psychiatric wards in general hospitals) over large mental institutions.15 These services 
promote rehabilitation and gradual incorporation of recently discharged, chronically 
mentally disturbed individuals into society. The intention is to create a support system for 
the affected people and is also one of the goals of the ‘Comprehensive Mental Health 
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Action Plan 2013-2020’.13 Accordingly, there has been a steady decline in the number of 
mental hospitals since 2011 and a pronounced increase (around 60%) in the number of 
psychiatric wards in general hospitals.13  
 
Studies have shown that social acceptance has gone a long way towards the 
reestablishment of mental health patients.16 The stigma associated with these disorders, 
stemming not only from ignorance and indifference but also from intolerance, leads to a 
vicious circle of discrimination in terms of basic necessities such as treatment, housing, 
employment, which then leads to a loss of self-esteem, resistance to treatment and relapse, 
ultimately making it difficult for people to recover.16,17 Literature suggests that in the 
United States, about 46% of homeless adults in shelter homes are living with severe mental 
illness, about 90% of suicidal deaths have a strong background of mental illness and an 
unbelievably increasing number of people are deemed disabled due to mental diseases 
every year and most of them are in the prime years of their lives.18,19 However, there is 
hope and there are global efforts to reduce misconceptions that people might harbor. The 
Japanese society of Psychiatry and Neurology recently changed the term for schizophrenia 
“Seishin-Bunretsu-Byo” which translates to “Split-Mind-Disease” and has replaced it with 
“Togo-Shitcho-Sho” which means “Integration Disorder.”17 Programs are being 
established with the intention of educating the public, protesting against possible 
discrimination, and promoting direct contact between the people suffering and the 
public.16,17 Psychiatry, as a practice, has seen a number of changes in recent times. It has 
now shifted gears towards clinical neuroscience, attempting to bring the basic etiology and 
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pathophysiology of the disorders to the forefront, hopefully giving us a better picture of the 
situation.20,21 
 
2. An overview of antipsychotic therapy in the United States:  
In the United States, mental disorders exact a huge toll on the economy.14 The NIMH has 
estimated that 1 in 4 Americans suffers from some form of mental disorder. Schizophrenia 
affects about 1%, and bipolar disorder affects about 2.6%, of the adult population in the 
US.3 In 2010, schizophrenia alone was responsible for nearly 400,000 hospitalizations.22  
 
There are two groups of antipsychotic drugs currently on the market to treat schizophrenia 
(Figure 1).23,24 The ‘first generation’ or typical antipsychotics, previously called 
neuroleptics, targeted dopamine D2 receptors and are effective against the positive 
symptoms of schizophrenia, but, inevitably, led to Parkinson-like extrapyramidal side 
effects (EPS).5 This class of agents is typified by CPZ (1) (Figure 1). The ‘second 
generation’ or atypical antipsychotics are mostly dual dopamine D2 and serotonin 5-HT2A 
receptor antagonists and/or inverse agonists effective against the positive as well as 
negative symptoms and cognitive deficits.24–26  
 
The atypical antipsychotics were initially thought of as being devoid of the side effects 
caused by typical antipsychotics; however, recent studies have shown that long-term use of 
these agents can also cause motor side effects (due to their high affinity at dopamine D2 
receptors), in addition to metabolic disorders and sexual dysfunction.27–29  
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The 1990s ushered in a new era in the field of antipsychotics with a number of atypical 
antipsychotic drugs being approved for clinical use.30 Although mainly indicated for the 
treatment of schizophrenia, these agents are now gaining importance in the management of 
other psychiatric conditions such as bipolar disorders and depression as well.31,32 
 
Clozapine (2) (Clozaril®) (Figure 1) was the first atypical antipsychotic drug to be 
approved for the treatment of schizophrenia.30 However, it was associated with serious 
blood conditions such as agranulocytosis, and is currently prescribed only for treatment-
resistant schizophrenia with indications of regular monitoring of blood cells.33–35  
 
Risperidone (3) (Risperdal®) (Figure 1) was introduced by Janssen-Cilag in 1993.24 In 
addition to monotherapy in schizophrenia, it is now also used as a clozapine-adjunct in 
clozapine-resistant patients of schizophrenia and schizoaffective disorders.36 It is, 
unfortunately, associated with metabolic disorders, weight gain, prolactin elevation, and is 
contraindicated in patients with dementia-related psychosis.37  
 
This was followed by olanzapine (4) (Zyprexa®) (Figure 1), which was introduced by Eli 
Lilly in 1996.23 It appeared to be sparing of agranulocytosis caused by its structural 
predecessor, clozapine, and there was minimal elevation of prolactin.38 However, there 
were reports of transient increases in serum transaminases (indicative of liver damage) and 
increased appetite that seemed to be of concern.39,40 Olanzapine is approved for use in the 
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United States as maintenance therapy for schizophrenia, as an adjunct to fluoxetine in 
refractory depression, and in bipolar disorder.41,42 Quetiapine (5) (Seroquel®) (Figure 1), 
was developed by AstraZeneca and was introduced in the Unites States in 1997.23 It is in 
clinical use for the treatment of schizophrenia, bipolar depression, and recently, for 
generalized anxiety disorder.43,44 Ziprasidone (6) (Geodon®) (Figure 1), was introduced in 
2001 and, although significantly helpful against motor and metabolic side effects common 
with the other atypicals, ziprasidone had a tendency to cause Qtc prolongation leading to 
cardiac events and, as with risperidone, is contraindicated in dementia-related psychosis.23  
 
Paliperidone (7) (Invega®) (Figure 1) is a metabolite of risperidone and an antipsychotic 
agent in it’s own right.45 It was approved for clinical use in 2006 and shares most of its 
side effects with risperidone.46  
 
A new class of atypical antipsychotics, termed ‘third generation’ antipsychotics, was 
introduced in the mid-2000s.47 Aripiprazole (8) (Abilify®) (Figure 1), an example of this 
class, was ranked the best-selling drug in the United States from the period of October 
2013 to September 2014.48 It differs from the other atypical antipsychotics in being a 
partial agonist at D2 receptors – sparing EPS, and a partial agonist (instead of an 
antagonist) at 5-HT2C receptors, thus avoiding the weight gain.49,50 It is used for the 
treatment of schizophrenia, bipolar I disorder, depression, and anxiety disorder.51 
Haloperidol (9) (Haldol®) (Figure 1) a typical antipsychotic developed in 1958, is still used 
clinically and accounted for 5% of the market prescriptions in 2011.23,48  
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Despite this clinical progress, there is still a sense of uncertainty in whether long-term use 
of antipsychotic medications really helps patients regain their independence and, 
eventually, lead a normal life.52  
 
3. Are antipsychotics helpful in the long run? 
“Could our drug-based paradigm of care, in some unforeseen way, be fueling this modern 
day plague?” questions Robert Whitaker in his book ‘Anatomy of an epidemic: Magic 
bullets, psychiatric drugs and the astonishing rise of mental illness in America’ when 
examining the growing pandemic of mental illness in the United States despite extensive 
biomedical facilities and drugs to combat the diseases.4  
 
The modern belief of psychiatry is to maintain schizophrenia patients on antipsychotic 
drugs long after even the acute stage of the illness has been relieved.52 Treatment of 
schizophrenia can be divided into three stages: an acute stage of psychosis, usually 
accompanied by hospitalization, a second stage that includes the next 2-3 years after the 
initial episode, and thereafter a third stage where active symptoms may or may not 
persist.53,54 The question many in the scientific community have raised is whether to keep 
patients on long-term medication – most of which carry their own plethora of side effects, 
or to discontinue medication gradually.52,55 The scientific community is also divided over 
whether antipsychotics have any efficacy in the long run, or simply make people so 
dependent that they are unable to resume an unaided life.4,56,57  
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In his book, Whitaker presents case studies of two scenarios: first, of people who have 
discontinued (mostly stealthily) medication and have made significant progress both 
personally and professionally, and second, of people who have come so far on the drugs 
that they seem to be functioning solely due to them. However, people on the drugs, while 
tolerating the side effects, still wonder what life would have been like while medication-
free.4  
 
Short-term double-blind studies have provided positive reviews about the effectiveness of 
antipsychotic use, with some patients even showing remission.52 However, most of the 
long-term studies are often a reflection of short-term discontinuation studies of the 
medication – wherein the first 6-10 months after drug discontinuation, patients either 
relapse or remain stable. Interestingly, relapse rates are much lower for patients who 
remain stable during these 6-10 months off-medication.52   
 
Long-term longitudinal studies are in contradiction to the positive short-term studies and 
some studies even question the long-term efficacy of drug treatment.52,56,57 In a 15-year 
longitudinal study, Harrow and Jobe52 reported that only about 40% of schizophrenia 
patients show one or more periods of recovery. More than 50% of the patients had 
recurring episodes of psychosis and some had psychotic episodes that were serious enough 
to affect normal functioning.57 Another 20-year, multi-follow-up longitudinal study 
reported that a substantial percentage of schizophrenia patients who were no longer on 
antipsychotic therapy were psychosis-free, had a lower relapse rate and recovered faster, 
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suggesting that, perhaps, not all schizophrenia patients need to be on drug-therapy for their 
entire lives.56 This shows that while long-term treatment with antipsychotic drugs does not 
guarantee recovery, the prognosis depends on the individual.58 The risks (which are 
numerous and dangerous)-benefit ratio of antipsychotic drug therapy need to be weighed 
carefully before pharmacotherapeutically dealing with this complicated and multifaceted 
disorder.58,59  
 
4. Therapeutic strategies and those under development: 
Most current efforts are mainly directed towards improving the pharmacokinetics and side- 
effect profiles of currently marketed antipsychotic drugs.23,28 While most drugs target 
dopamine D2 receptors, with varying degrees of binding affinity and efficacy (with most 
acting as D2 antagonists), efforts are being directed towards novel therapeutic targets for 
antipsychotic therapy.9,60,61 Some clinically-relevant developments are discussed. 
 
a. Improvements over current antipsychotic drugs: 
The major grievances against currently marketed atypical antipsychotics are their tendency 
to cause significant weight gain, metabolic disorders, cardiac problems and sedation, 
among others.58 These problems might be a result of additional multi-receptor interactions, 
such as those with 5-HT2C, H1, M1-M5 and α1-adrenoceptors.23,39 Structural modifications 
have attempted to achieve selectivity and avoid off-target interactions.  
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Iloperidone (10) (Fanapt®) (Figure 2) was approved by the USFDA in 2009 and is 
structurally related to risperidone (3).23,62 It has low affinity for H1 histamine and 
muscarinic receptors, so there is a lower chance of weight gain, sedation and metabolic 
disorders caused by the older atypical agents.23 However, its affinity for α1-adrenoceptors 
is sufficient to cause Qtc prolongation. Oral iloperidone is now recommended for the acute 
treatment of adults with schizophrenia.55  
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Figure 2. Structure of iloperidone in relation to risperidone.23 
 
 Lurasidone (11) (Latuda®) (Figure 3) is structurally similar to ziprasidone (6) and was 
approved for the treatment of schizophrenia in 2010.23,48 Apart from 5-HT2A and D2 
receptors, lurasidone is also a 5-HT7 receptor antagonist that has been shown to be helpful 
against the cognitive deficits of schizophrenia.63 Also, lurasidone has reduced affinity at 
α1-adrenoceptors and 5-HT2C receptors, and no affinity at H1 histamine or M1 muscarinic 
receptors leading to an improved cardiovascular profile, and a low liability of weight gain 
and sedation.23,63  
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Figure 3. Structure of lurasidone in relation to ziprasidone.23 
 
Another novel class of compounds that was actually developed in the 1980s but that has 
only recently been clinically explored is what have been termed ‘dopamine stabilizers.’64 
The clinically approved atypical antipsychotic drug aripiprazole (8) (Figure 1) belongs to 
this class.49 These compounds are either dopamine partial agonists or antagonists, 
depending on basal dopaminergic tone, and have the ability to interact with D2 dopamine 
receptors just enough to decrease the hyperdopaminergia of schizophrenia without carrying 
the risk of hypodopaminergia.49,64 Studies have shown that even after 80% occupation of 
D2 receptors, there are minimal chances of EPS.65 This group of compounds is being 
extensively researched and some of them have even reached clinical trials.23  
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b. Non-dopaminergic and non-serotonergic targets:  
Atypical antipsychotics are effective against the negative symptoms and cognitive deficits 
of schizophrenia in addition to the positive symptoms but their overall advantage over 
typical antipsychotics is only modest and they also come with their own side effects.66 In 
such scenarios, there is an acute need to explore other therapeutic targets.  
 
i. Glutamatergic drugs: The ‘NMDA hypothesis of schizophrenia’ (which will be discussed 
later) was established in 1995 based on the observation that NMDA receptor antagonists 
such as ketamine and phencyclidine (PCP) mimic not only the positive symptoms, shown 
by amphetamine, but also the negative and cognitive symptoms of schizophrenia.67 The 
metabotropic glutamate (mGlu) receptors belong to class C G-protein coupled receptors 
(GPCRs) and consist of 8 subtypes of which mGlu2 and mGlu3 (and recently, mGlu5) have 
been extensively studied with regards to schizophrenia (Table 1).68 
 
Table 1. Classification of metabotropic glutamate receptors adapted from Swanson et al.69 
 
Family receptor Coupling Localization 
Group 1   
mGlu1 Excitatory – Gαq coupled Postsynaptic at 
glutamatergic synapses and 
cerebellar localization in 
granular cell and parallel 
fibre layer 
 
mGlu5 Excitatory – Gαq coupled Postsynaptic at 
glutamatergic synapses, also 
in glial cells. High 
expression in forebrain 
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regions such as 
hippocampus and amygdala 
 
Group II 
 
  
mGlu2 Inhibitory – Gαi/o coupled Largely presynaptic 
glutamatergic localization, 
also high expression in 
forebrain regions such as 
hippocampus and amygdala 
 
 
mGlu3 Inhibitory – Gαi/o coupled Largely presynaptic 
glutamatergic localization, 
also high expression in 
forebrain regions such as 
hippocampus and amygdala 
 
Group III   
mGlu4 Inhibitory – Gαi/o coupled Both pre- (cerebellar parallel 
fibres) and postsynaptic 
localization 
 
 
mGlu6 Inhibitory – Gαi/o coupled Expression confirmed only 
in retinal bipolar ON cells. 
 
 
mGlu7 Inhibitory – Gαi/o coupled Only presynaptic inhibitory 
mGlu localized to active 
zone of synapses 
 
 
mGlu8 Inhibitory – Gαi/o coupled Largely presynaptic 
glutamatergic localization, 
also high expression in 
forebrain regions such as 
hippocampus and amygdala 
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 Evidence from the ability of mGlu2/3 orthosteric agonists [e.g. LY354740 (12) and 
LY379268 (13)] (Figure 4) to inhibit phencyclidine (PCP)-induced positive and negative 
symptoms led to mGlu2/3 receptors to be studied as novel targets for drug development.68 
However, since the orthosteric site of GPCRs in general is highly conserved among all the 
subtypes, it necessitated development of selective agents and, hence, positive allosteric 
modulators (PAM) of mGlu2/3 were investigated. A few examples of clinically relevant 
mGlu2 PAMs are LY487379 (14) (the first identified selective mGlu2-selective PAM) 
(Figure 4), biphenylindanone-A (BINA) (15) and JNJ-40411813 (16). JNJ-40411813 (16) 
(Addex and Janssen) and ADZ8529 (17) (AstraZeneca) (structure undisclosed) have 
reached clinical trials (Figure 4).23,68-70  
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Figure 4. Some agonists and PAMs at mGlu2 receptor with antipsychotic activity in 
preclinical and/or clinical studies.23,68 
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ii. Phosphodiesterase (PDE) inhibitors: These are inhibitors of the intracellular second 
messengers 3,5-cyclic adenosine monophosphate (cAMP) and 3,5-cyclic guanosine 
monophosphate (cGMP). Specifically, inhibitors of the subtype PDE10A, which is located 
primarily in the brain and the testes in mammals has been extensively studied and PF-
2545920 from Pfizer has been identified as a clinical candidate for the treatment of 
schizophrenia.23,71  
 
iii. Glycine transporter inhibitors: Following the NMDA hypothesis, one more avenue 
being explored to enhance glutamatergic signaling, especially to overcome the negative 
symptoms of schizophrenia, was to reinforce the effects of the NMDA receptor co-agonist 
glycine. This was achieved by the inhibition of the glycine transporter-1 (GlyT-1) on glial 
cells and is being examined clinically.72  
 
B. CONDITIONS ASSOCIATED WITH SEROTONIN IMBALANCE 
5-Hydroxytryptamine (5-HT) or serotonin (18) (Figure 5) was first identified as a 
vasoconstrictor in mammalian serum in 1948 and was also found in gastric mucosa, and to 
have an excitatory effect on intestinal smooth muscles.73,74 Thereafter, its presence in the 
central nervous system was established in invertebrates, rodents, and eventually in several 
species of mammals.73 The effects of modulating 5-HT levels (through activation of 5-HT 
receptors) by pharmacological agents such as lysergic acid diethylamide (LSD) (19) 
(Figure 5), led to the conclusion that 5-HT plays a key role in behavior.75,76 It is now 
known that 5-HT is not only responsible for neuronal development, memory, emotional 
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processing, depression, anxiety, schizophrenia, appetite, sleep and sexual behavior, but 
also for platelet aggregation and regulation of smooth muscles of the heart.77–80  
            
An increase and decrease of 5-HT can have profound effects on the body and the most 
evident result is on behavior. A few clinical effects of 5-HT imbalance on behavior are 
discussed.  
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Figure 5. 5-HT and representative structures of classical hallucinogens.81 
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1. Psychosis due to 5-HT agonists and /or hallucinogens:  
In order to pinpoint the origin of the effects he experienced after accidental chemical 
exposure in his laboratory, Albert Hofmann, a natural products chemist at Sandoz 
Pharmaceuticals in Basel, Switzerland, had deliberately self-administered 0.25 g of d-
lysergic acid diethylamide (LSD) in 1943.81,82 After a period of 40 minutes, his journal 
entry reported: “slight giddiness, restlessness, difficulty in concentration, visual 
disturbances, laughing”.82 This was followed by a loss of time, disorganized perception of 
space, dissociation, alternating restlessness and paralysis; and visual deformation that 
lasted hours after the other symptoms had abated.82 
 
Psychosis is an abnormal perception of reality (as described above) and can manifest itself 
as hallucinations, delusions, altered consciousness, delirium, cognition problems, and in 
certain cases, even death.81 Hallucinogens (classical hallucinogens and dissociatives) bring 
about these changes and are mostly used for their recreational potential, in certain religious 
experiences (where they are also referred to as entheogens), and are now increasingly 
being studied with respect to psychiatric diseases such as schizophrenia.81,83 
  
Classical hallucinogens mainly belong to two main chemical classes: the 
indolealkylamines and the phenylalkylamines (Figure 5). The indolealkylamines include 
LSD (19), N,N-dimethyltryptamine (DMT) (20), psilocin (21), and the phenylalkylamines 
include mescaline (22), 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) (23), 
and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) (24).83 
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After the almost simultaneous discovery of 5-HT and LSD, initial investigations found that 
LSD (19) interacted with 5-HT receptors to cause certain behavior changes, and the 
striking structural similarities between 5-HT and LSD warranted further examination when 
it was thought that 5-HT could be responsible for the actions mediated by LSD.76  
 
It can be concluded from radioligand binding work and studies on animal models such as 
drug discrimination (with DOM), head-twitch behavior, startle reflex, conducted in the 
past by our laboratory and several others that 5-HT is indeed involved in the mechanism of 
action of both classes of hallucinogens with 5-HT2A receptors (referred to as 5-HT2 at that 
time) being the key site of action.78-80   
 
LSD (19) was found to be a non-selective low efficacy agonist (or a partial agonist) at       
5-HT2A and 5-HT1 receptors.84 In fact, drug discrimination studies conducted by Glennon77 
have established that there is a correlation between the ED50 values of the drugs and their 
affinity at the 5-HT2A receptor.85 Additionally, studies with antagonists selective for 5-
HT2A and 5-HT2C, revealed that this hallucinogenic property is due to 5-HT2A and not 5-
HT2C receptors.86,87 The effects of these serotonergic hallucinogens are dose-dependent and 
resemble the earliest phases of schizophrenia, which include changes in mood, thought, 
intuition, perception of self and euphoria.88,89 The predominantly visual hallucinations 
brought about by these agents recreate those experienced in the acute stages of the disease, 
that become more auditory as the disease worsens. This is one of the tenets of the 
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‘serotonin hypothesis of schizophrenia’ and the effects of serotonin hallucinogens have 
been used to generate models of schizophrenia for research.89,90 
 
Activation of the 5-HT2A receptor in the prefrontal cortex leads to an increase in the 
excitatory postsynaptic potentials (EPSP) in the apical dendritic region of layer V 
pyramidal cells which indicates a release of glutamate.91 This has been supported with 
mGlu2/3 agonists and AMPA/kainate glutamate receptor antagonists.91,92 NMDA receptor 
antagonists such as PCP (25) and ketamine (26) (Figure 6) have been shown to recreate not 
only the positive symptoms of psychosis (such as those mediated by the serotonergic 
hallucinogens) but also the negative symptoms (depression, anhedonia, social withdrawal) 
and cognitive deficits of schizophrenia.93 This has given rise to the ‘NMDA hypothesis of 
schizophrenia’ and these models are considered to better depict the overall symptoms of 
schizophrenia.92  
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Figure 6. NMDA receptor antagonists capable of producing schizophrenia-like 
symptoms.81,92 
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2. Depression: 
Depression is a chronic, persistent mood disorder characterized by anhedonia, feelings of 
emptiness, worthlessness, lack of concentration, fatigue, increased or decreased appetite 
and an inexplicable need to ‘escape’.94 Depression can be life threatening and is 
responsible for an increasing number of suicides across the world.95 Evidence has pointed 
towards genetic (40-50% risk) as well as non-genetic factors, such as childhood trauma, 
stress, bereavement, and major lifestyle changes, in the pathophysiology of the disease.94,95  
 
Reserpine was found to mediate depletion of monoamine neurotransmitters and produce 
depression-like symptoms and is believed to be the foundation of the monoamine 
hypothesis of depression.96 The first two drugs showing antidepressant-like activity (Figure 
7) were discovered rather serendipitously. Iproniazid (27) and imipramine (28) (Figure 7) 
were obtained as a part of antituberculosis and antihistamine research, respectively, and 
were found to dramatically elevate the moods of hospitalized patients.96  
 
These drugs, initially called as ‘psychic energizers’4, were seen to increase the synaptic 
levels of 5-HT and norepinephrine (NE) by two different mechanisms: Imipramine (28) 
inhibited the reuptake of 5-HT, while iproniazid (27) inhibited monoamine oxidase 
(MAO), the enzyme responsible for metabolizing 5-HT and NE.96,97 Imipramine (28) has 
led to the development of several classes of marketed drugs inhibiting the reuptake of 5-
HT and NE such as tricyclic antidepressants [amitriptyline (29)], ‘selective serotonin 
reuptake inhibitors’ (SSRIs) [fluoxetine (30)], ‘norepinephrine reuptake inhibitors’ (NRIs) 
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[nortryptyline (31)] and ‘dopamine reuptake inhibitors’ [bupropion (32)] (Figure 7).98–100 
The discovery of iproniazid (27) delivered another class of antidepressants called the 
monoamine oxidase inhibitors (MAOIs) [isocarboxazid (33)] (Figure 7).101,102  
 
These drugs were developed based on the monoamine hypothesis of depression – that 
depression is caused by a deficiency of 5-HT and/or NE (and possibly, DA).91 However, 
this hypothesis could not explain why it took 2-4 weeks before activity of antidepressants 
was evident and research was extended to receptors and second messenger signaling 
pathways, mainly related to 5-HT.94,96 Different regions of the brain such as the 
hippocampus and the prefrontal cortex, amygdala, nucleus accumbens and the 
hypothalamus have been postulated to be involved in the cognitive problems, the lack of 
pleasure and the loss of appetite, reminiscent of depression.103,104  
 
Therapeutic strategies such as deep brain stimulation are practiced for certain treatment-
resistant depressions.94 Also, novel therapeutic targets such as the organic cation 
transporters (OCTs) are currently being explored to account for the fact that the available 
antidepressants, which mainly target the serotonin transporter (SERT), fail to provide relief 
to a considerable percentage of patients.105  
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Figure 7. Antidepressants of the past and of the present.94,99,100,102,106 
 
3. Anxiety disorders:  
The first antianxiety agent was also discovered by chance during drug development for 
another therapeutic target.107 The first antianxiety drug was meprobamate (Miltown®) (34), 
introduced by Wallace laboratories in 1955, and it was a descendent of mephenesin (35), 
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which was discovered for its tranquillizing and muscle relaxant properties, during 
antibiotic research (Figure 8).107 
H2N O O NH2
O O
CH3
CH3
CH3
O OH
OH
Meprobamate (34) Mephenesin (35)  
Figure 8. The first antianxiety agents.107,108  
 
According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-5), “anxiety disorders include disorders that share features of excessive fear and 
anxiety and related behavioral disturbances”.109 The disorder is characterized by fear of 
certain future events and the anticipation of reacting to them.109,110 Anxiety disorder is a 
class of disorders, each having its own specific trigger. The DSM-5 further classifies 
anxiety disorders into the following: separation anxiety, selective mutism, specific phobia, 
social anxiety disorder, panic disorder, agoraphobia, generalized anxiety disorder and 
substance/medication induced anxiety.109   
 
Recent neuroimaging studies have implicated a role of the amygdala, different regions of 
the orbitofrontal cortex, anterior cingulate, parietal and occipital cortices, in the 
pathophysiology of anxiety disorders.111 There is evidence that 5-HT1A receptors are 
involved in the perception of fear-related cues from studies conducted on homozygote as 
well as heterozygote 5-HT1A knockout mice.112 5-HT1A receptors are located 
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presynaptically (on serotonergic neurons in the raphe nuclei) and postsynaptically (on 
glutamatergic and GABAergic pyramidal neurons in the limbic, frontal and entorhinal 
cortices).112,113 Studies on transgenic mice have elicited a role of the postsynaptic 5-HT1A 
receptors located in the forebrain to modulate anxious behavior and 5-HT1A receptor 
knockout mice show resistance to benzodiazepine (common medications for anxiety) 
treatment.112,114  
 
5-HT1A receptors also play a role in the effect of SSRIs (first line of treatment) in anxiety 
treatment.115,116 In fact the 5-HT1A receptor antagonist pindolol hastens the action of SSRIs 
by preventing the inhibitory action of 5-HT1A autoreceptors that has been shown to delay 
the onset of action of SSRIs in humans.112,117 To further bolster this observation, positron 
emission tomographic (PET) examination with a radiolabelled selective 5-HT1A antagonist 
WAY-100635 has shown that there is a negative correlation between 5-HT1A binding 
affinity and anxiety scores, and suggested a role of partial agonists at 5-HT1A 
(postsynaptic) receptors in the treatment of anxiety.118 
 
 
The most commonly prescribed antianxiety agents for generalized anxiety disorder, panic 
disorder and social anxiety include the SSRIs and the SNRIs such as sertraline (36), 
escitalopram (37), paroxetine (38) (SSRIs), and venlafaxine (39) (SNRI), respectively 
(Figure 9).116 Benzodiazepines such as alprazolam (40) (Figure 9) are still used, however, 
they are associated with side effects such as sedation, physical dependence and impaired 
concentration. They also carry a risk of withdrawal symptoms and rebound anxiety.116,119 
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Figure 9. Antianxiety agents currently prescribed.116 
 
4. Schizophrenia: 
The symptoms of schizophrenia become evident as hallucinations (initially visual and then 
progressing to auditory), delusions and thought disorders (these are called as positive 
symptoms), social withdrawal, apathy, lack of affect and catatonia (these are known as 
negative symptoms); and cognitive and decision-making impairments (see Figure 
11).91,120,121 The genetic risk of schizophrenia is quite high and it is known that there is a 
50% chance for the identical twin of a schizophrenia patient to develop the disease. The 
type of household environment during childhood (abusive or emotionally distant parents) 
can also contribute.122  
    
 30 
Schizophrenia is neurodevelopmental rather than neurodegenerative in nature, suggested 
by the absence of inclusion bodies or gliosis, reminiscent of neurodegenerative diseases.123 
It has a varied phenotype and is subjective; hence modeling schizophrenia as a whole in 
animal models has been difficult.124 However, animal models of psychosis (e.g. LSD and 
PCP) have been successful to an extent, in recreating the positive and negative symptoms, 
and have been helpful in determining the brain regions affected.89,92 Neuroimaging and 
pharmacological advances have supported this and although we are far from completely 
solving the mystery of schizophrenia, we now know that the dopaminergic, serotonergic, 
glutamatergic and the GABAergic systems are involved (Figure 10).120,125 
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Figure 10. The neural circuits involved in schizophrenia, adapted from Freedman, R.120 
 
a. Symptoms and neuroanatomical changes: 
Schizophrenia as a disease can be divided into three stages: the prodromal stage, the 
acute/active stage and the residual stage.92 The outward symptoms (Figure 11) that help in 
diagnosis generally appear in the mid-20s.120 However, the actual onset of the disease (the 
prodromal stage), which can be as early as in the teens, often gets shrouded under the guise 
of the emotional and physical changes of adolescence and adjustment to early adulthood.122 
 
    
 32 
POSITIVE SYMPTOMS 
HALLUCINATIONS 
DELUSIONS 
 
NEGATIVE SYMPTOMS 
SOCIAL WITHDRAWAL 
ANHEDONIA 
LACK OF CONCENTRATION 
FLATTENING OF AFFECT 
DISORGANIZATION OF 
THOUGHTS 
 
COGNITIVE DEFICITS 
INABILITY TO FOCUS 
SHORT TERM MEMORY 
DEFICITS 
 
 
Figure 11.  The three major symptoms of schizophrenia.92,121 
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One of the hypotheses to explain the perceptional abnormalities (hallucinations) and an 
inability to differentiate between the internal ‘voices’ and extraneous environmental 
stimuli (contributing to delusions) is hyperactivity of the thalamus.125 The thalamus is 
responsible for filtering sensory input and is under an inhibitory influence of GABAergic 
neurons. This inhibition of the thalamus by GABAergic neurons is controlled by dopamine 
D2 receptors.125,126 An abnormally active dopaminergic system can lead to disinhibition of 
the thalamus, which is now unable to filter out information, rendering the patient incapable 
of discerning the ‘real’ from the ‘fabricated’.125,127 
 
In schizophrenia, the Glu-GABA-Glu-DA pathway (Figure 10) is impaired leading to an 
overactive limbic dopaminergic system.128 In the non-psychotic brain, the Glu neurons 
from the thalamic sensory relay nucleus (Figure 10) are connected to a smaller GABAergic 
interneuron that has an inhibitory influence on the glutamatergic cortical pyramidal neuron, 
leading to a lower firing rate. This regulates the dopaminergic output in the limbic system 
(Figure 10).120,125 However, compromised NMDA receptors on the GABAergic 
interneuron prevent GABA from exerting its inhibitory action on the cortical pyramidal 
neuron. The result is an overdose of dopamine in the limbic system and this can lead to 
psychosis.128 There is also a failure of the inhibitory interneurons and the inhibitory 
neurotransmitter GABA, leading to impaired synaptic connections between cortical and 
pyramidal neurons.125 
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There are certain striking neuroanatomical changes observed in the schizophrenic brain 
such as a marked decrease in the migration of neurons to the cortex from the underlying 
white matter, white matter disorganization in the prefrontal cortex and lower pyramidal 
cell density.123,125,129 A hallmark of schizophrenia, which is also present in first-episode, 
non-medicated patients, is enlarged ventricles (especially third and lateral ventricles) and 
diminished volume of the hippocampus and the superior temporal cortex.123 There is a 
distinct volume reduction in the frontal lobe, especially in the prefrontal and orbitofrontal 
regions.130 Abnormalities in the basal ganglia and thalamus have also been reported. All 
these could contribute to the negative symptoms and the cognitive deficits of the 
disorder.125,130,131  
 
Although all aspects are not hereditary, there is increasing evidence of a pre-developmental 
lesion in the brain, which can interact with certain environmental stressors and this in 
already predisposed people can precipitate the onset of the disease.122,123   
 
b. The dopamine hypothesis of schizophrenia:  
The dopamine hypothesis of schizophrenia initially stemmed from the discovery that 
antipsychotics such as CPZ (1) elicited their effects by decreasing DA concentration in the 
mesolimbic region of the brain, that is, they function as DA receptor antagonists.132 In fact 
it has been shown that antipsychotic potency is related to the binding affinity of 
antipsychotic agents at DA receptors.131 
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This was followed by the observation that stimulants such as amphetamine could lead to   
effects quite similar to the positive symptoms of schizophrenia.131,133 The dopamine 
hypothesis postulated that schizophrenia is caused by overstimulation of dopaminergic 
receptors in the mesolimbic region (leading to hallucinations and delusions) and a lack of 
dopamine at the nucleus accumbens leading to the anhedonia and lack of motivation.132   
 
The dopamine hypothesis that gained ground during the 1960s led to a thorough 
investigation of the dopaminergic tracts in the brain. It was shown that stimulation of DA 
receptors in the nigrostriatal pathway by amphetamine led to stereotyped motor effects, 
and inhibition of these receptors by the antipsychotic agents led to the extrapyramidal side 
effects commonly experienced with these agents.132 This further bolstered the hypothesis.  
 
However, it soon came to light that antipsychotic agents were only effective against the 
positive symptoms and had little, if any, effect against the negative symptoms and 
cognitive deficits.92,133 Atypical antipsychotic drugs, especially clozapine (2) and 
risperidone (3), had greater affinity towards 5-HT2A receptors over D2 receptors, a faster 
dissociation rate at D2 receptors, and could help against the positive as well as the negative 
symptoms of schizophrenia.134 Additionally, they also had a lower tendency for causing 
extrapyramidal side effects.135  
 
Thus, the dopaminergic system could not explain all the parameters of the disease and the 
serotonin hypothesis of schizophrenia came along. 
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c. The serotonin hypothesis of schizophrenia:  
5-HT and psychosis have been linked since the almost simultaneous discovery of LSD (19) 
and 5-HT (18) in the late 1940s.80 As discussed earlier (section B), research on the 
serotonergic system has evolved hand-in-hand with studies on hallucinogens such as LSD 
(19), DMT (20), mescaline (22), and DOM (23), which are agonists and/or partial agonists 
at 5-HT receptors, 5-HT2A in particular.84 The hallucinations and bizarre experiences 
created by these hallucinogens were very similar to the positive symptoms of the initial 
stages of schizophrenia.92 The serotonin hypothesis postulated that hyperactivity of 5-HT 
in the cerebral cortex and the locus ceruleus (Figure 10) is responsible for schizophrenia.91  
 
The first atypical antipsychotic, clozapine, further supported the serotonin hypothesis. 
Unlike typical antipsychotics such as CPZ (1) and haloperidol (9), it was effective against 
the positive, negative, as well as cognitive symptoms of schizophrenia and did not result in 
EPS that was a hallmark of classical antipsychotic treatment.30,134,135 The atypical 
antipsychotics had a higher affinity at 5-HT2A receptors than at dopamine D2 receptors, and 
acted as dual serotonin-dopamine antagonists.136  
 
MRI and PET imaging studies of the cerebral cortex of schizophrenia patients revealed 
certain neuroanatomical changes in the serotonergic system.131 Schizophrenia has been 
associated with a hyperactive dorsal raphe nucleus (DRN) (Figure 10) and overdriven 
serotonergic signaling to the cerebral cortex, especially in the anterior cingulate nucleus 
(ACC) and the dorsolateral frontal lobe.91 Post mortem brain samples from schizophrenia 
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patients have shown an increase in 5-HT, especially in the putamen, globus pallidus, 
nucleus accumbens and the basal ganglia.131 There was a decrease in 5-HT in the 
hypothalamus, medulla oblongata, and hippocampus.131,137 This was accompanied by a loss 
of grey matter in the ACC, potentially explaining the decreased utilization of ATP in the 
frontal lobe.91  
 
Although the atypical antipsychotics are certainly more sparing in their EPS-causing 
liability, they have only a modest efficacy over the typical antipsychotics, especially with 
regard to the negative symptoms, and a considerable number of patients did not respond to 
treatment.68,138 The psychosis generated by NMDA antagonists such as PCP (25) and 
ketamine (26) produced the entire spectrum of symptoms and model the disease much 
better.92 This focused attention on the role of glutamate in the pathophysiology of 
schizophrenia.  
 
 
 
 
 
 
 
 
 
    
 38 
d. The NMDA hypofunction/glutamate hypothesis of schizophrenia: 
The complete clinical syndrome of schizophrenia captured by NMDA receptor antagonists 
such as PCP and ketamine is the foundation of the glutamate hypothesis of schizophrenia 
that was put forward by Olney and Farber in 1995.68,92  
 
Classical hallucinogens such as LSD and mescaline, enhance glutamatergic 
neurotransmission in the prefrontal cortex by increasing the frequency of the excitatory 
postsynaptic potentials (EPSPs) in the apical dendritic region of the layer V pyramidal 
cells.91,139 As discussed earlier, malfunctioning NMDA receptors on the interneurons 
(Figure 10) could lead to loss of GABAergic control of the dopaminergic influence on the 
mesolimbic regions.68,91 An increase in the glutamatergic neurotransmission and a lack of 
inhibition by GABA can perhaps explain the positive symptoms of schizophrenia.91 A 
potential explanation for the negative symptoms and cognitive deficits is an overactivation 
of GABA interneurons by a hyperactive glutamate signaling and the resulting 
overinhibition of the dopaminergic pathway to the mesocortical region.68,91,131  
 
Currently, the pharmacological treatment of schizophrenia entails one or more of the 
atypical antipsychotics (Figure 1).12,23 However, since the DA and 5-HT hypotheses could 
not completely explain the behavioral or the neuropathological changes occurring in 
schizophrenia, glutamate receptors are now being explored as potential antipsychotic 
targets.23,68 Additionally, a pharmacological agent targeting both the serotonergic and 
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glutamatergic aspects of schizophrenia (a heteromer of 5-HT2A and mGlu2 receptors) could 
be more efficacious in treating the disorder.9  
 
C. THE 5-HT CLASS OF RECEPTORS:  
5-HT receptors (5-HT1-5-HT7) can be divided into seven main classes that can further be 
divided into several subclasses.80 With the exception of 5-HT3, which is a ligand-gated ion 
channel, all other 5-HT receptors belong to the class A GPCR superfamily of 
receptors.80,140 They consist of seven transmembrane-spanning helices and have an 
extracellular N-terminus and an intracellular C-terminus.80 Listed below in Table 2 is the 
current classification of 5-HT receptors into seven main classes and their respective 
subclasses.80  
 
Table 2. Classification of 5-HT receptors adapted from Glennon and Dukat.80 
Populations and 
Subpopulations 
 
Second messenger 
System 
Currently 
Accepted 
Name 
 
Comments 
5-HT1 
5-HT1A 
 
AC (-) 
 
5-HT1A 
 
 
Cloned and pharmacologic          
5-HT1A receptors 
5-HT1B AC (-) 
 
5-HT1B Rodent homolog of 5-
HT1B receptors 
 5-HT1Bβ   A mouse homolog of h5-
HT1B receptors 
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5-HT1D 
 
 
 
          5-HT1Dα 
 
5-HT1Dβ 
 
  
5-HT1E 
 
5-HT1Eα 
 
5-HT1Eβ 
 
5-HT1F 
5-HT2 
5-HT2 
 
5-HT2F 
 
 
 
 
 
AC (-) 
 
AC (-) 
 
 
AC (-) 
 
 
 
AC (-) 
 
 
 
PI 
 
PI 
 
 
 
 
 
h5-HT1D 
 
h5-HT1B 
 
 
5-HT1E 
 
 
 
5-ht1F 
 
 
 
5-HT2A 
 
5-HT2B 
 
Sites identified in binding 
studies using human and 
calf brain homogenates 
A cloned 5- HT1D 
subpopulation 
 
 
 
Human counterpart of rat 
5-HT1B 
 
 
Sites identified in binding 
studies using brain 
homogenates and cloned 
receptors 
 
 
 
 
 
 
Cloned h5-HT1E 
 
 
 
Cloned mouse homolog of 
5-HT1F receptors 
 
 
Cloned h5-HT1F receptors 
 
 
 
Originally known as          
5-HT2 
 
 
5-HT2-like, found in rat 
fundus 
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5-HT1C 
 
5-HT3 
5-HT4 
5-HT4S 
 
5-HT4L 
 
5-HT5 
5-HT5A 
 
5-HT5B 
 
5-HT6 
 
5-HT7 
PI 
 
Ion Channel 
AC (+) 
 
 
 
 
 
? 
 
? 
 
AC (+) 
 
AC (+) 
5-HT2C 
  
5-HT3 
5-HT4 
 
 
 
 
 
5-HT5A 
 
5-HT5B 
 
5-HT6 
 
5-HT7 
Originally known as           
5-HT2C 
 
Ligand-gated ion channel 
 
Short form of cloned         
5-HT4 receptors 
 
 
Long form of cloned        
5-HT4 receptors 
 
 
 
Cloned mouse, rat and    
h5-HT5 receptors 
 
 
Cloned mouse and rat       
5-HT5 receptors 
 
 
Cloned rat and h5-HT 
receptor 
 
 
Cloned rat, guinea pig and 
h5-HT7 
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1. 5-HT2A RECEPTORS AND SOME LIGANDS TARGETING THEM: 
 
5-HT2A receptors are a major target of atypical antipsychotics, antidepressants, 
hallucinogens and other psychoactive drugs, as well as some antihypertensive drugs.77,140 
They are GPCRs and are coupled to the Gα/q subunit of the heterotrimeric G-proteins 
(Figure 12).141 
 
 Activation of 5-HT2A receptors leads to several downstream events such as the activation 
of phospholipase C (PLC), catalyzing hydrolysis of phosphatidylinositol 4,5-bisphosphate 
(PIP2) to inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 then releases 
calcium ions (Ca2+) from the endoplasmic reticulum (ER) which then activates inwardly 
rectifying chloride channels (Figure 12).80,140,141  
Gαq$
β$
γ$
5(HT$
GIRK3$
Cl($
Ca2+$
ER$
DAG$PLC$
DAG$
IP3$
PIP2$
OTHER$EFFECTS$
ER: Endoplasmic reticulum 
 
Figure 12. The second messenger signal transduction pathway of 5-HT2A receptors.80,141  
 
    
 43 
Tools such as radioactively labeled ligands, in situ hybridization, RT-PCR and 
immunocytochemistry have revealed the CNS presence of 5-HT2A receptors in the cerebral 
cortex, basal forebrain, hippocampus, amygdala, hypothalamus, superior colliculus, latero 
dorsal tegmental nucleus, spinal cord motor neurons, sympathetic and sensory neurons and 
the peripheral presence in vascular, gastrointestinal smooth muscles, platelets and retina.141 
 
Initially, 5-HT receptor binding sites were investigated using a number of radioactively 
labeled ligands such as [3H]-5-HT, [3H]-LSD, and [3H]-spiperone.141 Spiperone (41) was 
selective for 5-HT2A over 5-HT2C (about 1000 fold) however; it had high affinity for 
dopamine D2 receptors (Figure 13).142 Ketanserin (42) was the first ligand to selectively 
label 5-HT2A receptors (referred to as 5-HT2 receptors or S2 receptors back then) (Figure 
13).143 It was devoid of activity at 5-HT1 receptors and had minimal affinity for dopamine 
D2 receptors. It became a prototypic 5-HT2 antagonist with high binding affinity (Ki = 3.5 
nM at 5-HT2A and Ki = 50 nM at 5-HT2C receptors in rat frontal cortex)143 and has 
remained a radioligand of choice for investigations at 5-HT2 receptors for over two 
decades.142–144  
 
DOI is a 5-HT2A agonist (highly selective for 5-HT2 sites) and is a hallucinogen.145 Our 
laboratory had previously reported that the R(-) stereoisomer is more active.145,146 Its 
radiolabeled form, [125I]-R(-)-DOI is used to label 5-HT2A receptors that were traditionally 
labeled with antagonists such as spiperone, ketanserin and partial agonists such as LSD. 
[125I]-R(-)-DOI led to the labeling of the low density, high affinity sites for  5-HT2A 
agonists.147  
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Figure 13. Radioligands commonly used to label 5-HT2A receptor sites.142,146  
 
 
 
 5-HT2A receptors have been a subject of great interest since atypical antipsychotic agents 
such as clozapine (2) and risperidone (3) were found to be dual serotonin-dopamine 
antagonists (SDAs) and having a higher binding affinity for 5-HT2A receptors over 
dopamine D2 receptors.8,30 In the late 1990s, it was observed that some atypical 
antipsychotic agents could inhibit the constitutive activity of 5-HT2A receptors and 
possessed inverse agonist activity.26  
 
2. THE 5-HT2A-mGLU2 HETEROMER: 
The 5-HT2A receptor specifically forms a heterodimer with the mGlu2 receptor.61 The two 
receptors have been shown to co-localize in mouse cortical slices and neuronal primary 
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cultures in autoradiographic studies (Figure 14) and interact to downregulate the Gα/q 
signaling of 5-HT2A receptors and upregulate the Gi/o signaling of mGlu2 receptors.9,61 
 
(A) 
(B) 
 
Figure 14. Overlay of 5-HT2A and mGlu2 receptors in mouse somatosensory cortex (A), 
and mouse cortical primary culture (B).61  
 
Clozapine (2) and risperidone (3) were found to crosstalk (downregulate the Gα/q signaling 
of 5-HT2A receptors and upregulate the Gi/o signaling of mGlu2 receptors when the two 
receptors are coexpressed) at the 5-HT2A-mGlu2 heterodimer and this target is currently 
being explored with respect to the pathophysiology of schizophrenia and the mechanism of 
action of certain hallucinogens.9,61  
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CHAPTER III: SPECIFIC AIMS 
 
 
 
 
The pharmacological and biochemical profile of risperidone (3) was extensively explored 
in the mid-1980s – around the time it was realized that excessive DA might not be the only 
contributing factor in schizophrenia.131,148 The serotonergic component of antipsychotic 
activity was gaining increasing importance with the discovery that several 5-HT receptor 
(specifically 5-HT2A, referred to as 5-HT2 sites then) antagonists (Figure 15) such as 
spiperone (41) inhibited the pharmacological actions of the 5-HT receptor agonist 
tryptamine (TRY) as well as apomorphine (APO)-induced stereotypy with potency being 
directly related to binding affinity.149 Ligands having a ‘mixed’ or dual serotonin-
dopamine antagonism (SDA) profile, such as risperidone (3) (ED50 = 0.028 mg/kg) and 
pirenperone (43) (ED50 = 0.020 mg/kg) (Figure 15) dose-dependently attenuated the LSD-
cue in drug discrimination studies, and differed from the selective 5-HT2A antagonist 
ritanserin (44) (ED50 = 11.6 mg/kg), which was not a very potent blocker of the LSD-cue, 
and the classical D2 receptor antagonist haloperidol, which did not block the                  
LSD-cue.150–154  
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Figure 15. Representative structures of 5-HT2A antagonists.155,156 
 
Risperidone (3) is said to be a prototype of centrally active ligands having optimum 
dopamine D2 receptor and 5-HT2A receptor binding affinity and antagonist activity.24,148,155 
In fact, atypical antipsychotics have a greater affinity for 5-HT2A receptors, as compared to 
D2 receptors and Meltzer had defined a ratio of D2/5-HT2A binding affinities, with a higher 
value being conducive for atypical antipsychotic-like activity.25  
 
The development of risperidone (Figure 16), stemmed from the need to integrate 
antiapomorphine and anti-tryptamine activities in a single centrally active ligand with good 
bioavailability.149,157  
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Figure 16. The development of risperidone from butyrophenones.157 
 
The development of risperidone began with two structurally related butyrophenones – 
benperidol (also known as benzperidol) (45) and lenperone (46) having affinity for the 
dopamine D2 receptor (Figure 16).157 Benperidol and lenperone had two aromatic groups 
separated from the central nitrogen atom by 4 carbon atoms and their structures could be 
considered as two ‘halves’ or ‘fragments’ around the central nitrogen atom (Figure 
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17).142,157 As both ligands bound to dopamine D2 receptors (Table 3), it was believed that 
the benzoyl moiety of lenperone had pharmacophoric similarities with the 
benzimidazolone moiety of benperidol.157 
F
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Lenperone (46) 
 
Figure 17. The ‘halves’ or ‘fragments’ of benperidol and lenperone.157 
 
Structural combinations of the fragments of benperidol and lenperone were then 
synthesized and evaluated for binding affinity and activity. Combining the two 
benzimidazolone fragments led to domperidone (47), which had affinity for peripheral DA 
receptors and activity only in the APO-induced emesis test in dogs suggesting peripheral 
activity and limited or no central activity.157 A combination of benzimidazolone with the 
benzoyl fragment led to declenperone (48) and milenperone (49), which were centrally 
active dopamine D2 antagonists with weak 5-HT2A antagonist activity (Table 3).157 
 
Further, several modifications to the benzimidazolone ring eventually led to the 
quinazolinedione ring system, represented by ketanserin (42).144,157 This increased the       
5-HT2A antagonist activity and imparted a 100-fold selectivity over D2 receptors. 
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Ketanserin had high affinity and functional activity at 5-HT2A receptors and limited central 
and peripheral D2 antagonist activity (Table 3).144,157,158  
 
Replacement of the quinazolinedione ring with several different saturated and unsaturated 
heterocyclic ring systems led to the development of pirenperone (43), a potent 5-HT2A and 
D2 receptor antagonist, having ∼8-fold selectivity for 5-HT2A receptors over dopamine D2 
receptors.157 However, it suffered from poor oral bioavailability. In a quest to develop 
metabolically stable molecules, changes were made on the right side of pirenperone and its 
analogs, giving rise to ritanserin (44), which had high selectivity for 5-HT2A receptors over 
D2 receptors.155  
 
Another approach to deter metabolism and increase bioavailability was based on the 
isosteric replacement of the benzoyl fragment with a benzisoxazole ring, giving rise to 
risperidone (3).148,157 Risperidone was centrally active and had excellent oral 
bioavailability. It was a potent antagonist at both receptors with about 20-fold selectivity 
for 5-HT2A (Ki = 0.16 nM) over D2 (Ki = 3.1 nM) and also had affinity for α1-adrenoceptors 
and histamine H1 receptors in the nanomolar range.157,159 Risperidone seemed to combine 
the favorable structural features of all its predecessors in terms of affinity and activity at D2 
and 5-HT2A receptors.  
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Table 3. Binding affinity and functional activity profile of risperidone and its predecessors 
adapted from Megens et al.157 
 
  
Receptor binding Ki  (nM) 
 
Activity against central 5-HT2A 
and D2 receptors ED50 (mg/kg, 
s.c.) 
 
Agent 5-HT2A D2 TRY (5-HT2A) APO (D2) 
Benperidol  6.60 0.35 0.29        0.0093 
Lenperidol Not tested 4.60 0.39        0.085 
Declenperol 2.40 9.30 2.40        0.44 
Milenperone 9.20 3.90 0.51        0.025 
Domperidone      330 0.90      > 40   > 40 
Ketanserin 2.10       220 2.40   > 40 
Pirenperone 2.10         16.00 0.11        0.098 
Ritanserin 1.20         23.00 0.26  >160 
Risperidone 
    Paliperidone 
0.16 
         0.22 
3.10 
         4.10 
0.13 
          0.22 
       0.15 
       0.39 
 
 
*Radioligand binding studies were performed in rat frontal cortex homogenates with [3H]-
spiperone. TRY and APO-assays studied inhibition of bilateral clonic seizures and agitation 
induced by TRY and APO, respectively.157  
 
 
In order to compare its serotonergic and dopaminergic activity components, risperidone (3) 
was explored for its in vitro and in vivo affinity and activity and was compared to 
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ritanserin (44) (a centrally acting selective 5-HT2A antagonist) and haloperidol (9) (a 
selective D2 antagonist).148,150  
 
Similar to ritanserin, risperidone showed antagonist activity in all tests related to central 
and peripheral 5-HT2A receptors, such as clonic seizures and tremors in rat forepaws 
induced by TRY, mescaline- and 5-hydroxytryptophan (5-HTP)-induced twitches with 
ED50 values of 0.014 mg/kg, 0.019 mg/kg and 0.016 mg/kg, respectively, and was more 
potent than ritanserin.150 
 
As regards activity against D2 receptors, risperidone antagonized central and peripheral 
dopaminergic activities such as apomorphine-induced emesis in dogs, amphetamine- and 
cocaine-induced agitation and stereotypies (Table 3).150,157 While haloperidol seemed to 
have a narrow dose range of 1:3.5 for all effects including locomotion, risperidone had a 
dose range of 1:10, excluding effects on locomotion, which were above this broad range.150  
 
Risperidone was found to be 10 times more potent at central 5-HT2A receptors than at 
central dopamine D2 receptors.160 
 
That risperidone had an antipsychotic-like profile different from haloperidol and other 
typical antipsychotics, was evident from the fact that it was a very potent LSD antagonist 
(ED50 = 0.028 mg/kg) in drug discrimination studies.153 Haloperidol (selective D2 
antagonist) does not affect the discriminative stimulus and ritanserin (selective 5-HT2A 
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antagonist) is not a very potent blocker (ED50 = 11.6 mg/kg) of the discriminative 
stimulus.150,152 In an open trial, risperidone (2-8 mg p.o. for 28 days) was effective in 
improving the condition of schizophrenia patients resistant to typical antipsychotics and 
having a major component of negative symptoms, without inducing EPS.161  
 
It was believed that the 5-HT2A component of the activity could be responsible for the 
effect of risperidone on negative symptoms of schizophrenia, as selective 5-HT2A 
antagonists such as pipamperone and ritanserin had demonstrated antidepressant-like 
properties and reduced catalepsy in rats.162 This hypothesis was further supported by 
electrophysiological studies that showed that a marked antagonism of 5-HT2A receptors (as 
shown by risperidone) could lead to a release of DA from the midbrain, which in turn 
could lead to release of DA in the nucleus accumbens and prefrontal cortex, thus 
circumventing the symptoms of lack of affect and concentration.8,160  
 
Risperidone proved to be unique in its receptor occupancy profile when compared to 
haloperidol (9) and clozapine (2) (another atypical antipsychotic). Apart from binding 
primarily to 5-HT2A receptors (clozapine binds primarily to histamine H1 receptors and 
haloperidol to D2 receptors), risperidone had a shallow occupancy curve at D2 receptors in 
the striatum and mesolimbic regions – suggesting a gradual increase in the occupancy of 
the receptor with increasing doses (Figure 18).159 Risperidone occupied 50% of 5-HT2A 
and dopamine D2 receptors at a dose of 0.0075 and 2.5 mg/kg s.c., respectively. At a dose 
at which 50% of D2 receptors are occupied, there is full occupancy of 5-HT2A sites, which 
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as previously described, can be helpful against negative symptoms.8,160 Also, the gradual 
occupation of D2 receptors suggests that at a lower dose and with partial occupation, 
risperidone might be helpful against positive symptoms without inducing EPS.  
(A) (B)  
Figure 18. The receptor occupancy profile of risperidone (ο), clozapine (☐) and 
haloperidol (Δ) at 5-HT2A receptors (A), and dopamine D2 receptors (B).8  
 
Physiologically, risperidone is metabolized by three major pathways in humans, rats and 
dogs leading to active and inactive metabolites: alicyclic hydroxylation, oxidative N-
dealkylation and cleavage of the benzisoxazole ring (Figure 19).163 The major active 
metabolite is paliperidone (7), which is the product of hydroxylation at the 9-position.157 7-
Hydroxylated (7-OH) 50, dihydroxylated 51, benzisoxazole ring cleavage products 52 and 
oxidative N-dealkylated 53 and 54 also form a small percentage of the metabolites.163 One 
of the metabolites in dogs, which is also a putative metabolite in humans, is 55 and it is a 
part of the current as well as past investigations by our laboratory.164  
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Figure 19. Metabolism of risperidone adapted from Mannens et al.163  
 
Although paliperidone and risperidone differ by a hydroxyl group, they possess similar 
binding affinity for both 5-HT2A and D2 receptors (risperidone possesses a slightly higher 
affinity for both receptors).45 Several groups have attempted to explore the possible 
pharmacological and/or downstream signaling consequences of this structural difference 
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and have found differences at the mitochondrial, neuronal firing and synaptic plasticity 
level.45,165 However, since the hydroxyl group could contribute in terms of additional 
interactions at the receptor and also change the physical and chemical properties, further 
studies are needed to validate the exact role of the hydroxyl group and that is a part of the 
current investigation.  
 
Similar to several other GPCRs (e.g. α1A- and β2-adrenergic and 5-HT2C receptors), 5-HT2A 
receptors possess constitutive activity and stimulate PIP2 hydrolysis in the absence of 
agonist stimulation.166,167 This phenomenon was shown in 5-HT2A receptors by a single 
amino acid mutation (C322K). Risperidone (and even paliperidone later on) was shown to 
inhibit the constitutively activated PIP2 hydrolysis and to possess inverse agonist 
activity.166  
 
The inverse agonist activity of risperidone was evident by another approach. Similar to 
clozapine (another atypical antipsychotic and inverse agonist at the 5-HT2A receptor), 
risperidone crosstalks in the 5-HT2A-mGlu2 heteromer in such a way as to balance the Gi-
Gαq signaling and possessing a high balance index (BI) [BI = ΔGi - ΔGq].9 Through the 
crosstalk, risperidone downregulates the unusually high Gαq signaling back to basal level 
and maintains the balance between the Gi-Gq signaling, which is disrupted in 
schizophrenia.9    
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Risperidone possesses some structural features, which confer upon it a unique balance of 
receptor affinity and functional activity, quite different from structurally related 
predecessors.  
 
The specific aims of the current investigation are:  
1. Determination of the minimal structural features responsible for the antagonist 
activity of risperidone/paliperidone at 5-HT2A receptors – Deconstruction of 
risperidone/paliperidone 
1a. Deconstruction of risperidone/paliperidone into smaller analogs and assessing their 
functional activity and binding affinity   
1b. Investigating the role of the hydroxyl group of paliperidone 
 
Deconstruction will involve the systematic removal of specific functional groups of 
risperidone to generate analogs lacking some features, which will be tested for functional 
activity and binding affinity by electrophysiological assays and radioligand binding 
studies, respectively.  
 
2. Investigation of the structural differences between risperidone and ketanserin and 
the role of the two halves of risperidone in its activity – Elaboration of risperidone 
2a. Examination of structural hybrids of risperidone and ketanserin 
2b. Investigation of the role of the right half of risperidone in its functional activity 
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2c. Investigation of the role of the benzisoxazole ring in the functional activity and     
binding affinity of risperidone  
2d. Investigating the role of Arien’s hypothesis in the antagonist activity of risperidone  
 
Elaboration will involve the substitution of the left and right halves of risperidone with the 
left and right halves of ketanserin. The potential role of the right half of risperidone in 
antagonist activity will be explored by making it as similar to 5-HT as possible.  The 
analogs will be tested for binding affinity and functional activity by radioligand binding 
studies and electrophysiological assays, respectively.  
  
3. Molecular modeling studies to understand the binding mode of risperidone and its 
analogs at 5-HT2A receptors  
Homology models of the 5-HT2A receptors will be constructed and the compounds will be 
analyzed for their binding poses and interactions with amino acids at the receptors by 
docking and scoring. The interactions will be validated by previous site-directed 
mutagenesis data and quantified by performing Hydropathic INTeraction (HINT) studies.  
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CHAPTER IV: APPROACH, RESULTS AND DISCUSSION 
 
 
 
 
A. DECONSTRUCTION OF RISPERIDONE: 
1. Approach: 
The medicinal chemistry principles of ‘deconstruction-reconstruction-elaboration’ were 
used to examine the structural features contributing to the antagonist activity of risperidone 
and paliperidone at 5-HT2A receptors.168  
 
This approach basically helps to understand which functional groups making up the 
structure of a compound contribute to its activity and binding affinity. The study begins 
with deconstruction, which involves the systematic removal of functional groups of the 
parent compound, to generate analogs lacking some features. The smaller analogs lacking 
certain features of the parent compound are then tested for functional activity and/or 
binding affinity. The change in the activity and/or affinity compared to the parent 
compound reflects the role of the functional group that is removed.168 For example, if 
removal of a carbonyl group leads to a 20-fold decrease in affinity, this indicates that the 
polar interactions that the carbonyl group is capable of making might be important for 
binding affinity. Similarly, if removal of a phenyl group leads to a negligible increase or 
decrease in activity, this suggests that the phenyl group does not contribute significantly to 
activity, and can be removed or replaced.   
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Deconstruction helps to simplify the structure to the minimum structural features 
responsible for activity and affinity. This is helpful in determining a pharmacophore for 
that particular activity.  
 
The structure of risperidone/paliperidone was systematically deconstructed and its 
structural features were explored as shown in Figure 20. 
R = H; Risperidone (3) 
     R = OH; Paliperidone (7) 
 
N
N
O
CH3
N
ON
F
R
 
Figure 20. Approach to the deconstruction of risperidone/paliperidone. Circled regions 
represent structural features that were excised.  
 
 
Risperidone can be divided into two halves: 6-fluoro-3-(4-piperidinyl)-1,2-benz[d] 
isoxazole (right half) and 2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one 
(left half) connected by an ethyl linker. The halves were explored further to determine their 
respective contribution towards activity and affinity (Figure 21). 
 
Our laboratory had in the past explored the structure-activity relationships (SAR) of 
ketanserin (42) by deconstruction (tested on the frontal cortical homogenates of male 
Sprague-Dawley rats using [3H]-ketanserin]).143 We have used a similar approach in our 
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study of risperidone (Figure 20). Figure 21 shows all the deconstructed analogs of 
risperidone included in the present study.  
N
N
N
O
CH3
ON
F
N
N
O
ON
F
N
N
ON
F
H
N
ON
F
H3C
N
ON
F
H
N
ON
H3C
N
ON
N
N
O
ON
F
OH
56
57
55
58
60
61
59
R = H; Risperidone (3)
R = OH; Paliperidone (7)
R
 
Figure 21. The halves of risperidone/paliperidone and the deconstructed analogs. 
 
As a starting point for the current investigation, the 6,7,8,9-tetrahydro-4H-pyrido[1,2-
a]pyrimidin-4-one ring system comprising the left half of risperidone was opened to give 
the tertiary amide, a compound retaining the carbonyl group, 56.  The carbonyl group of 56 
was removed (reduced) to afford 57. These analogs retain part of the hydrophobicity of the 
6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system. Herndon et al.143 had 
previously reported similar modifications on the structure of ketanserin, and the analogs 
retained binding affinity for the receptor (Figure 22). 
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Figure 22. A comparison of the deconstruction of ketanserin and risperidone. Binding data 
are provided for ketanserin and its deconstructed analogs at 5-HT2A receptors.143 
 
Similar deconstruction studies were also conducted with paliperidone (i.e., 59). A 
comparison of the result of the two series will be informative regarding the role of the 
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hydroxyl group – whether it plays a role in binding affinity and/or activity, or whether it is 
merely tolerated.  
 
Thereafter, the left portion of risperidone was removed to give the N-methyl analog 58 that 
retains a part of the alkyl bridge connecting the two halves of risperidone in the form of a 
methyl group. This methyl group was then removed to give analog 55, which was reported 
previously by our laboratory.164 Herndon et al.143 had similarly deconstructed and tested 
the right half of ketanserin (42) (i.e., 62) and reported that there is a dramatic loss of 
binding affinity (∼120 fold) when compared to ketanserin (Figure 22).143 Removal of the 
methyl group of 63 to afford the desmethyl analog 62 resulted in a ∼3-fold lower binding 
affinity over the N-methyl analog 63. (Figure 22).143  
 
Based on the preliminary results of the functional activity of 55, the precise role of the 
benzisoxazole ring system and its substituents was probed where the benzisoxazole ring 
was kept constant and the substituents were varied (Figure 21). Herndon et al.143 had 
reported that the desfluoro analog (i.e., 66) of 62 (Figure 22) displayed ∼8-fold decreased 
affinity and more than 900-fold decreased affinity compared to ketanserin (42), suggesting 
a role of the fluoro group in binding.143 Evaluation of desfluoro analogs 60 and 61 should 
reveal the importance of the fluoro group in the binding affinity of risperidone and its 
deconstructed analogs.  
 
 
    
 64 
2. Results: 
a. Chemistry:  
The synthesis of the deconstructed analogs of risperidone was carried out in collaboration 
with others in our laboratory. Rakesh Vekariya initially synthesized the compound without 
the carbonyl group 57 and the synthesis is outlined in Scheme 1. Compounds 56 and 57 
were re-synthesized through a common intermediate 67, which was synthesized by 
reacting freshly distilled piperidine (68) with the acid chloride 4-chlorobutyryl chloride 
(Scheme 1).169 The synthesis of compound 56 was initially attempted by heating at reflux, 
however, the reaction did not go to completion and the yields were poor. Subsequently, a 
Finkelstein reaction was tried under pressure in a screw-cap vial that drove the reaction to 
completion and the yield was increased from 1% to 10%. The free base of 56 when 
subjected to reduction with BH3-THF, followed by acidic hydrolysis, afforded 57 (Scheme 
1).  
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Scheme 1. Synthesis of compounds 56 and 57a 
NH N
O
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N
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F
N
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68 67
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57
c
b
a
 
aReagent: (a) 4-Chlorobutyryl chloride, Et3N, CH2Cl2, room temperature, 75 h; (b) 6-
fluoro-3-(piperidin-4-yl)benz[d]isoxazole, K2CO3, KI, MeCN, screw-cap vial, 88 °C, 16 h; 
(c) (1) BH3-THF, THF, reflux, 2 h; (2) 6N HCl, reflux, 1 h.  
 
 
The paliperidone counterpart 59 was synthesized similarly. However, the starting material, 
(±)3-hydroxypiperidine (69), had a free hydroxyl group which could potentially interfere 
with the subsequent reactions that would be conducted at the amine group. Hence, attempts 
were made to protect this group using a trimethylsilyl ether (TMS), which was 
unsuccessful with starting material being recovered. Thereafter, the benzyl ether of (±)3-
hydroxypiperidine (71) was synthesized and the ensuing reactions gave good yields; 
however, subsequent efforts to remove the benzyl protecting group proved fruitless. 
Debenzylations with hydrogenolysis at atmospheric pressure and under pressure with 
various reaction conditions were attempted (Scheme 2). 
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Scheme 2. Initial attempts to synthesize compound 59a   
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aReagent: (a) Benzylchloride, tetraethylammonium bromide, CH2Cl2, room temperature; 
(b) TMSCl, imidazole, DMF, room temperature, 20 h; (c) 4-chlorobutyryl chloride, Et3N, 
CH2Cl2, room temperature, 75 h; (d) 6-fluoro-3-(piperidin-4-yl)benz[d]isoxazole, K2CO3, 
KI, MeCN, screw-cap vial, 88 °C, 16 h; (e) HCl/EtOH, EtOH, Pd/C (5%), hydrogen 
balloon; (f) HCl/EtOH, EtOH, Pd/C (10%), hydrogen balloon; (g) HCl/EtOH, EtOH, Pd/C 
(10%), Parr hydrogenator, 15 psi; (h) HCl/EtOH, EtOH, Pd/C (10%), Parr hydrogenator, 
55 psi. 
 
A literature review provided information about the potential role of amines (a specific case 
of a tertiary amine was reported) in hindering O-debenzylation by hydrogenolysis.170 Since 
our compound also contained a tertiary amine, it was speculated that the amine might be 
hampering the last step of O-debenzylation.   
 
Eventually, the reaction was attempted without protecting the hydroxyl group of (±)3-
hydroxypiperidine (69) and, although the yields were moderate (∼30%), the reactions 
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proceeded to finally yield 59. Compound 59 was synthesized through the intermediate 74, 
(Scheme 3) and was obtained as an oxalate salt because its hydrochloride salt was 
hygroscopic and difficult to isolate.  
 
 
Scheme 3. Synthesis of compound 59a 
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aReagent: (a) 4-Chlorobutyryl chloride, Et3N, CH2Cl2, room temperature, 75 h; (b) (1) 6-
fluoro-3-(piperidin-4-yl)benzo[d]isoxazole, K2CO3, KI, MeCN, screw-cap vial, 88 °C, 16 
h; (2) oxalic acid, MeOH, Et2O. 
 
 
The synthesis of compound 55 was reported by Strupczewski et al.,171 and was replicated 
as outlined in Scheme 4. The amino group of isonipecotic acid (75) was protected by 
formylation. This was followed by conversion to N-formylisonipecotic acid chloride (77), 
which was generated in situ and was monitored by IR spectroscopy to denote the loss of 
the broad peak of the –OH group of the carboxylic acid of isonipecotic acid (75) at 3200 
cm-1. The acid chloride was subjected to acylation by Friedel-Crafts acylation reaction with 
1,3-difluorobenzene to afford 78. This reaction was limited by the condition of AlCl3, 
which was used in the same equivalence as the starting materials. The reaction was highly 
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sensitive to moisture, and freshly sublimed AlCl3 was used for this step. The oxime 79 was 
synthesized for the intramolecular displacement of the 2-fluoro moiety to afford 
benzisoxazole 80. TLC suggested formation of both E and Z isomers, of which only the Z 
isomer is believed to participate in the cyclization reaction. The formamide group was 
removed by acidic hydrolysis (Scheme 4). Compound 58 was synthesized by N-
methylation of 55 using a Eschweiler-Clarke reaction.143 The subsequent   commercial 
availability of 6-fluoro-3-(piperidin-4-yl)benz[d]isoxazole (55) facilitated the preparation 
of additional product.  
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Scheme 4. Synthesis of compounds 55 and 58a 
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aReagent: (a) (1) HCOOH, Ac2O, 65 °C, 1 h; (2) room temperature, 16 h; (3) vacuum 
distillation; (b) SOCl2, DMF, room temperature, 6 h; (c) 1,3-difluorobenzene, AlCl3, 
ClCH2CH2Cl, reflux, 45 h; (d) hydroxylamine hydrochloride, NaOH/H2O, EtOH, reflux, 
96 h; (e) NaH (toluene washed), DMF, room temperature, 48 h; (f) (1) conc. HCl, EtOH, 
reflux, 3 h; (g) (1) HCOOH, HCHO, EtOH, reflux, 10 h; (2) HCl/Et2O. 
 
 
The syntheses of compounds 60 and 61 followed the procedure reported by Strupczewski 
et al.171 and are outlined in Scheme 5. Due to the unavailability of a commercial Grignard 
reagent, 4-chloro-N-methylpiperidine (81) was converted to a Grignard reagent in situ and 
reacted with the cyano compound 2-fluorobenzonitrile to give the acylated product 82. 
This compound was cyclized by a one-pot conversion of the acylated product oxime and, 
which by intramolecular displacement of fluorine, afforded 61. The N-methyl group was 
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removed by converting it to a phenyl carbamate 83, followed by basic hydrolysis to yield 
60 (Scheme 5). 
Scheme 5. Synthesis of compounds 60 and 61a 
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aReagent: (a) (1) 4-Chloro-N-methylpiperidine, THF, Mg, bromoethane, reflux, 1 h; (2) 
room temperature, 2-fluorobenzonitrile, reflux, 3 h; (3) room temperature, 36 h; (4) NH4Cl, 
50 °C, 2 h; (5) HCl/Et2O; (b) (1) KOH (85%), hydroxylamine hydrochloride, 
ethoxyethanol, reflux, 6 h; (2) HCl/Et2O; (c) (1) NaOH, toluene, phenyl chloroformate, 
reflux, 24 h; (2) petroleum ether; (d) KOH (85%), EtOH, reflux, 48 h; (2) HCl/Et2O.  
 
 
 
b. Functional activity studies:  
The functional activity studies of risperidone (3) and compounds 55-58 were performed in 
Dr. Logothetis’ laboratory by Jason Younkin, Amr Ellaithy, Dr. Lia Baki and Sneha Shah, 
and two biological assay systems were used: calcium imaging by an epifluorescence assay 
using the Ca2+ sensitive dye Fura2AM in HEK293 cells stably expressing 5-HT2A 
receptors, and the two-electrode voltage-clamp (TEVC) electrophysiological assay in a 
Xenopus laevis oocyte heterologous expression system.172,173 Risperidone (3) and 
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preliminary studies with paliperidone (7) were carried out in the TEVC 
electrophysiological assay system.  
 
The calcium imaging assay reflects the amount of calcium released from the endoplasmic 
reticulum (Figure 12) on activation of IP3 receptors on the ER by IP3 when the 5-HT2A 
receptor is stimulated. The potentiometric dye Fura2AM is sensitive to calcium and 
chelates the released calcium and fluoresces at two wavelengths: 340 nM and 380 nM. A 
ratio of the fluorescence at 340/380 nM is an indication of the concentration of calcium 
released. At a concentration of 100 µM for compounds 55, 57 and 58 and 32 mM for 
compound 56, the compounds by themselves generated no calcium signal (Figure 23).  
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Figure 23. Compounds 55 (A), 56 (B), 57 (C), and 58 (D) did not generate the calcium 
signal indicating the intracellular release of calcium (figures provided by Dr. Lia Baki). 
 
As seen from Figure 23, the carbonyl compound 56 was not only difficult to ‘wash-off’ 
from the receptor but also inhibited the agonist activity of 5-HT. Compounds 55, 57 and 
58, on the other hand could be ‘washed off’ so that 5-HT could exert its full agonist 
activity at the receptor. However, when compounds 55-58 were applied in the presence of 
5-HT, the compounds dose-dependently inhibited the activity of 1 µM 5-HT. Risperidone 
was also included in this study. A typical dose-response curve (Figure 24) for the 
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compounds was generated and the half maximal inhibitory constants (IC50 values) for the 
compounds were calculated (Table 4). 
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Figure 24. Dose-response curves for risperidone and compounds 55-58 by the calcium 
imaging assay. Results are from a single experiment (figures provided by Dr. Lia Baki). 
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The TEVC assay measures the inhibition of current from the inwardly-rectifying potassium 
channel GIRK4* associated with the 5-HT2A receptor (Figure 25).172 Here, the K+ channel 
functions as a “reporter” of the ligand-mediated Gαq activity. In the assay, the heterologous 
oocyte system co-expressing the 5-HT2A receptor and the GIRK4* channel is perfused with 
a solution of high concentration of K+ (HK), which sets a baseline current (sensitive to 
Ba2+ ions). On stimulation of the receptor by the ligand, the Gαq subunit activates PLC 
leading to the hydrolysis of PIP2 and release of IP3 and DAG. The activity of GIRK4* is 
PIP2-dependent, and a decrease in PIP2 concentration (due to its hydrolysis) leads to 
current inhibition through GIRK4*. The IP3-mediated release of calcium from the ER leads 
to activation of chloride channels, (which is indicated by a spike at the onset of the 
inhibitory current due to 5-HT) and phosphorylation of GIRK4* (Figure 25). The 
phosphorylation of GIRK4*, also inhibits the potassium current, which is measured and 
gives an indication of Gαq-mediated activity of the compound under study.174  
 
The GTP-bound Gαq subunit is then acted upon by RGS2, which is a GTPase-activating 
protein, converting GTP to GDP, and leading to the reassociation of Gαq subunit with the 
βγ subunit, thereby stopping the current inhibition due to the ligand.174 
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GIRK4* + 5-HT 
RGS2: Regulator of G-protein 
signaling 2  
 
Figure 25. A schematic representation of the measurement of Gαq-mediated activity at        
5-HT2A receptors by the TEVC assay.172  
 
The TEVC assay is ∼10-fold more sensitive than the calcium imaging epifluorescence 
assay. Preliminary studies with risperidone indicated an IC50 value of 57 nM and in the 
presence of 5-HT, it brought the agonist activity of 5-HT (the normalized Gαq activity 
considered as 100%) down to ∼20%. Compounds 55-58 inhibited the 5-HT-mediated Gαq 
activity with IC50 values of 2800 nM, 199.7 nM, 16.8 nM and 101 nM, respectively 
(Figure 26).  
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IC50 = 57 nM IC50 = 2800 nM
log[compound 55], M
A B
 
C
IC50 = 199.7 nM
log[compound 56], M
IC50 = 16.8 nM
log[compound 57], M
D
 
E
IC50 = 101 nM
log[compound 58], M
 
Figure 26. The dose-response curves for inhibitory activity exhibited by risperidone (A), 
compounds 55 (B), 56 (C), 57 (D), and 58 (E) (figures provided by Jason Younkin). 
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In the preliminary data, at a concentration of 10 µM, compounds 55-58 demonstrated Gαq 
activity by themselves (Figure 27) with about 25% (55), 45% (56), 70% (57) and 30% (58) 
of the activity of 5-HT (100% Gαq activity). However, at a concentration of 50 µM the 
compound lacking the carbonyl group, 57, showed an agonist activity of ∼150% (Figure 
27B).  
55 58 56 57 
A B 
57     µM  
Figure 27. The positive efficacy of compounds 55-58 (A), and the potential ‘superagonist’ 
activity of compound 57 (B) (figures provided by Jason Younkin). 
 
To ascertain whether the activity exhibited by the compounds is solely G-protein coupled 
or due to independent activity at the GIRK4* channel, they were tested in an assay system 
expressing the channel alone.  Compound 57 showed strong agonist activity at the channel.  
These studies have been continued and additional data generated (see Appendix A). 
 
When the 5-HT2A receptor is activated by 5-HT, the release of calcium from the ER leads 
to an increase in the intracellular positive ion concentration. This produces an initial 
inward spike in the electrophysiological tracing after the application of the concentration of 
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5-HT under study (Figure 28). The sharp inward spike then continues upwards to show 
inhibition of the GIRK4* channel current, which is measured by the assay. The 
intracellular calcium release simultaneously activates chloride channels (inward), 
producing a strong outward current (reflected as an outward spike in the 
electrophysiological tracing). This outward chloride spike was not observed with 
compounds 55-58 (data shown for 58 in Figure 28). Also, the compounds produced a 
rather broad inward peak instead of the sharp spike shown by the application of 1 µM of  
5-HT. This is similar to the lack of calcium signal observed with the calcium imaging 
assay.  
58 
B 
H3C
N
ON
F
A 
5-HT 
58 
 
Figure 28. The outward current due to the inward movement of chloride ions and the 
inward current due to the intracellular release of calcium ions after application of 5-HT 
(A), and the lack of inward and outward current after the application of the compounds, 
represented by the N-methyl compound 58 (figures provided by Jason Younkin). 
 
It was interesting to note that in the preliminary studies with paliperidone (7), a 
concentration of 5 µM in the absence of 5-HT, led to a reversal of basal current, which is 
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reminiscent of inverse agonist activity. This study with paliperidone is currently under 
further investigation.  
 
As discussed earlier, risperidone, similar to clozapine, crosstalks in the 5-HT2A-mGlu2 
heteromer and this is an indication of their inverse agonist activity. The crosstalk is evident 
from a decrease in 5-HT induced Gαq activity of the 5-HT2A portion, and a simultaneous 
increase in glutamate-induced Gi activity of the mGlu2 portion of the heteromer.9 
Compounds 55-58 were tested in the heteromer expressed in the Xenopus laevis oocyte 
heterologous expression system, wherein the 5-HT2A-mediated Gαq activity was measured 
by the inhibition of the GIRK3 channel and the glutamate-mediated Gi activity was 
measured by the activation of the GIRK4* channel. Compound 55 was able to crosstalk 
across the heteromer system (Figure 29), while compounds 56-58 were incapable of 
exerting this effect. This crosstalk effect is currently under further investigation.  
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55 55 
A B 
 
Figure 29. The crosstalk in the 5-HT2A-mGlu2 heteromer system exhibited by compound 
55 (figures provided by Jason Younkin). 
 
c. Radioligand binding studies:  
The radioligand binding assay was conducted in Dr. Javier González-Maeso’s laboratory 
by Dr. José L. Moreno. These studies were performed in HEK293 cells expressing 5-HT2A 
receptors with [3H]-ketanserin (Ki = 2 nM) as the radioligand. Non-specific binding was 
determined in the presence of 10 µM methysergide and competition curves were generated 
and analyzed by nonlinear regression to derive the dissociation constants (Ki values) 
(Figure 30). 
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Ki = 5.22 ± 1.40 nM
A
 
Ki = 42.97 ± 16.33 nM
Compound 56
CB
Compound 55
Ki = 75.75 ± 30.77 nM
 
Ki = 35.20 ± 7.32 nM
Compound 57
D
Compound 58
E
Ki = 18.77 ± 11.12 nM
 
Figure 30. Radioligand binding affinity at 5-HT2A receptors expressed in HEK293 cells of 
risperidone (A), compounds 55-58 (B), (C), (D), (E), respectively (figures provided by Dr. 
José L. Moreno). 
Binding affinities of risperidone and the deconstructed analogs 55-58 were determined in 
this assay system and resulted in Ki values of 5.22 ± 1.40 and 75.75 ± 30.77, 42.97 ± 
16.33, 35.20 ± 7.32 and 18.77 ± 11.12 nM, respectively (Table 4). 
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Table 4. Results from the functional and binding assays. 
 Calcium 
imaging 
assay 
(IC50, nM) 
TEVC assay; 
percent 
reduction of       
5-HT-induced 
Gαq  activity*  
Radioligand 
binding assay, 
Ki ± SEM 
values (nM) 
N
N
O
CH3
N
ON
F
 
Risperidone (3) 
 
H
N
ON
F
 
 
5,761 
 
 
 
 
 
 
 
17,930 
 
∼20% 
IC50  = 57 nM 
 
 
 
 
 
∼25% 
IC50  = 2800 nM 
 
5.22 ± 1.40 
 
 
 
 
 
 
 
75.75 ± 30.77 
55    
 
N
N
O
ON
F
 
56 
 
 
 
15,500 
 
 
∼45% 
IC50  = 199.7 nM 
 
 
42.97 ± 16.33 
N
N
ON
F
 
57 
H3C
N
ON
F
 
 
53,490 
 
 
 
 
 
 
 
10,720 
 
∼70% 
IC50  = 16.8 nM 
 
 
 
 
 
 
∼30% 
IC50  = 101 nM 
 
35.20 ± 7.32 
 
 
 
 
 
 
 
18.77 ± 11.12 
58   
 
 
 
*Preliminary data. 
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3. Discussion:  
The calcium imaging epifluorescence assay showed that compounds 55-58 are capable of 
inhibiting the activity of 5-HT at the receptor. As the compounds do not produce any 
calcium signal (which is a reflection of activity in this assay) by themselves, it suggests 
antagonist activity.  
 
The TEVC electrophysiological assay system, however, owing to its sensitivity, indicated 
a positive efficacy of compounds 55-58 that at the tested concentration of 10 µM, was 
lower than the activity produced by 5-HT at 1 µM. Compounds 55, 56 and 58 inhibited the 
activity of 5-HT, essentially bringing it down to their respective efficacies. This is in 
agreement with the definition of a partial agonist, which is a ligand having positive 
efficacy lower than that of a full agonist, and antagonizes the activity of the full agonist by 
competing for the orthosteric site (the primary binding site of the endogenous ligand).175  
 
The positive efficacy of compound 57 is considerably higher than the other compounds 
and at a concentration of 10 µM, the activity of 57 when tested by itself, was close to that 
of 5-HT (1µM). At a concentration of 10 µM, 57 inhibits the action of 5-HT to 70% (its 
own efficacy; Figure 27) fitting the profile of a high potency partial agonist. However, 
when compound 57 was tested at a concentration of 50 µM, it produced an activity of 
∼150% (Figure 27), suggesting enhanced agonist activity or potential ago-allosteric 
activity (see Appendix A).  
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To examine this in greater detail, additional studies were performed. The agonist action of 
compound 57 could be due, in part, to its effect on the GIRK4* channel. Indeed, when 
examined in cells lacking 5-HT2A receptors, 57 still produced an “agonist” effect (see 
Appendix A).  
 
The action of 57 could also involve an allosteric effect. Hence, it was important to 
determine whether or not 57 binds at the 5-HT2A orthosteric site. Radioligand binding 
studies revealed that 57 binds at the orthosteric site with high affinity (Ki = 35 nM) 
suggesting that it exerts at least part of its activity through the orthosteric binding site of 
the receptor.  
 
The fact that the compound retaining the carbonyl group 56 and without the carbonyl 
group, 57, show comparable binding affinity, suggests that the carbonyl group might not 
be essential for binding at the 5-HT2A receptors.   
 
The high binding affinity of the N-methyl analog 58 (only ∼3 fold lower than risperidone) 
suggests that the 6-fluoro-3-(1-methylpiperidin-4-yl)benz[d]isoxazole portion of 
risperidone is sufficient to maintain  high binding affinity at the receptor. Similar to their 
ketanserin counterparts, the N-methyl analog 58 and the desmethyl analog 55 differ by ∼4-
fold in their binding affinity, suggesting additional interactions by the N-methyl group at 
the receptor.  
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The functional data shows that the analogs lacking certain features of risperidone have 
positive efficacy. As the structure of risperidone is deconstructed, the analogs 55-58 have 
some positive efficacy and reflect partial agonist activity (or potential superagonist activity 
in the case of 57). However, when compared to the activity of risperidone (3), which could 
be due to noise and other factors, and which cannot be eliminated or accounted for at this 
moment, compounds 55-58 could actually be behaving as neutral antagonists (supported 
by the lack of the Ca2+ signal in both functional assays). This would be in agreement with 
the studies carried out by our laboratory in the past, reported by Iwamura et al. in which 55 
showed antagonist activity.164  
 
The TEVC functional assay system has shown that the smaller deconstructed analogs of 
risperidone, compounds 55 and 58 have a comparable inhibitory activity at 5-HT2A 
receptors (Table 4). The radioligand binding assay has shown that the N-methyl compound 
58 is comparable in affinity to risperidone. These results suggest that the right half of 
risperidone, [(6-fluoro-(3-piperidinyl)benz[d]isoxazole] is important for its activity and/or 
affinity.  
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B. ELABORATION OF RISPERIDONE: 
1. Approach: 
The ‘elaboration’ approach of the medicinal chemistry principle of deconstruction-
reconstruction-elaboration’ was utilized to determine the role of the two ‘halves’ of 
risperidone in imparting it with it’s inhibitory activity.  
 
Elaboration involves replacing part of the molecule (which was thought to impart a 
particular effect) with new substituents. In the current investigation, the right and the left 
half of risperidone was replaced one at a time to investigate the role of that particular half 
in its activity at the receptor. Ketanserin (42) is a prototypical antagonist at the 5-HT2A 
receptor.144,158 Structurally, ketanserin can also be divided into two halves (Figure 31). In 
fact, the right half of ketanserin, 4-(4-fluorobenzoyl)piperidine [bioisoteric with the right 
half of risperidone – 6-fluoro-3-(4-piperidinyl)-1,2-benz[d]isoxazole] is known to possess        
5-HT2A receptor antagonist activity.176 Our laboratory had reported in the past that the 6-
fluoro-3-(4-piperidinyl)-1,2-benz[d]isoxazole portion of risperidone (i.e., compound 55) 
possesses this antagonist activity.164  
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Figure 31. A comparison of the left and the right ‘halves’ of ketanserin and risperidone. 
 
The present investigation aimed not only to determine what structural features of 
risperidone are responsible for its functional activity, but also what makes it different from 
ketanserin, which is structurally similar. Ketanserin and risperidone possess striking 
structural similarities (the right halves) and some structural differences (the left halves). 
We replaced the left and the right halves of risperidone and ketanserin and created two 
hybrid compounds 84 and 85 (Figure 32). The binding affinity and the functional activity 
of these structural hybrids should be informative about the effect that the structures of 
risperidone and ketanserin have on their functional activity and binding affinity.  
 
The right hand portion of ketanserin (i.e., 63) binds with >35-fold lower affinity than its 
parent143 (Figure 22) whereas its benzisoxazole counterpart (i.e., 58) binds only with 3-fold 
lower affinity than risperidone (Table 4). This suggests that the right half of risperidone 
contributes more towards binding affinity than the right half of ketanserin.  
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Risperidone (3) Ketanserin (42)
84 85  
Figure 32. The structures of risperidone (3), ketanserin (42) and hybrids 84 and 85. 
 
If compound 84 loses inhibitory activity, it will tell us that the right half of risperidone is 
indeed playing a role in the activity. Similarly, if compound 85 is inactive, this will mean 
that the left half of risperidone contributes and is important for activity or the left half of 
ketanserin does not contribute to the antagonist activity.  
 
As reported previously by Iwamura et al.,164 the structure of the deconstructed analog of 
risperidone, compound 55, is similar to that of structurally rigid tryptamines such as          
RU 28253 (86) and RU 24969 (87) (Figure 33) of the tetrahydropyridylindole class of 
compounds, which are potent 5-HT1 and 5-HT2 receptor agonists.164,177 Yet, Iwamura et 
al.164 reported 55 to be a potent 5-HT2A receptor antagonist. In the present investigation 
analogs 88 and 89, which are structurally related to RU 28253 (86) and RU 24969 (87) but 
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still have the 6-fluoro group reminiscent of 55 (Figure 33), were synthesized to examine 
their binding affinity and functional activity at 5-HT2A receptors. The results should reveal 
the role of the benzisoxazole ring in maintaining binding affinity and activity at the 5-HT2A 
receptor. As discussed earlier, the role of the ring substituents (fluoro group) of compound 
55 was probed by synthesizing analogs lacking the fluoro group (i.e., 60 and 61). 
Similarly, in the present study, the role of the substituents was probed further by replacing 
the 6-fluoro group with a 5-methoxy group (i.e. 90). Compound 90 is similar to RU 28253 
(86) and RU 24969 (87), which are known to be agonists at 5-HT receptors. If compound 
90 is an antagonist, it would suggest that the benzisoxazole ring system might play a role 
in converting an agonist (RU 24969) to an antagonist. 
H
N
NH
F
H
N
NH
HN
NH
H
N
NH
F
H
N
ON
OCH3 OCH3
OCH390
8988
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Figure 33. Comparison of the benzisoxazole ring with tetrahydropyridylindole ring.164,177 
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We replaced the right half of risperidone with one of the constrained tryptamines from our 
study to give compound 91 (Figure 34). The purpose of this replacement is dual. First, we 
will be investigating the role of the right half of risperidone by replacing it with another 
group. Second, by replacing the benzisoxazole ring with an indole ring, we are making the 
right half of risperidone more like 5-HT and other agonists at 5-HT receptors. If compound 
91 retains antagonist activity it will support the Ariens hypothesis of conversion of 
agonists to antagonists on addition of bulky substituents on amines. However, if 91 does 
not exhibit antagonist activity, it could mean that either the left half of risperidone is not 
contributing to its antagonist activity, or the right half of risperidone is important for the 
activity.  
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5-HT (18)
90
RU 24969 (89)
92
Risperidone (3)  
Figure 34. Elaboration of risperidone with constrained tryptamine analogs.  
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2. Results: 
a. Chemistry 
The synthesis of the elaborated analogs of risperidone was carried out in collaboration with 
Urjita Shah from our laboratory, who synthesized compound 84, the synthesis of which is 
outlined in Scheme 6.  
 
Compound 84 was synthesized by a Finkelstein reaction between the heterocyclic alkyl 
chloride 92 with 4-fluorobenzoylpiperidine hydrochloride in the presence of 2 equivalents 
of K2CO3, because the amine is present as its hydrochloride salt, and KI as the catalyst. 
The solvent, acetonitrile (MeCN), was utilized because with N,N-dimethylformamide 
(DMF), the yields were poor. Also, the literature suggests that for reactions with 
compound 92, solvents such as MeCN, i-PrOH and isobutanol work better than DMF.178 
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Scheme 6. Synthesis of compound 84a 
N
N
O
CH3
Cl
N
N
O
CH3
N
O
F
x 2HCl
92 84
a
 
aReagent: (a) 4-(4-fluorobenzoyl)piperidine hydrochloride, K2CO3, KI, MeCN, reflux,      
16 h. 
 
Multiple synthetic routes were attempted for the synthesis of compound 85, and with 
different reaction conditions for a particular synthetic route (Scheme 7). The ketanserin-left 
half counterpart of the heterocyclic alkyl halide 93 was initially reacted with N,N-
diisopropylethylamine (DIEA) or Hünig’s base in the presence of MeCN. The reaction did 
not go to completion and neither the product, nor the starting material, could be isolated. 
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Scheme 7. Initial attempts to synthesize compound 85a 
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aReagent: (a) (1) 6-Fluoro-3-(piperidin-4-yl)benz[d]isoxazole, N,N-diisopropylethylamine 
(DIEA), MeCN, room temperature, 23 h (2) 50 °C, 2h (3) reflux, 18 h; (b) 6-fluoro-3-
(piperidin-4-yl)benz[d]isoxazole, K2CO3, KI, DMF, reflux, 18 h; (c) 6-fluoro-3-(piperidin-
4-yl)benz[d]isoxazole,  K2CO3, KI, MeCN, 16 h; (d) 6-fluoro-3-(piperidin-4-
yl)benz[d]isoxazole, screw-cap vial, 88 °C, 16 h. 
 
 
Next, based on the procedure for similar analogs reported by our laboratory in the past,143  
a Finkelstein reaction was attempted, initially in the presence of DMF, which had a 
tendency of giving multiple products from which the desired product was difficult to 
isolate. Then MeCN was used as a solvent, however, it produced the same results as with 
DMF. Another method was reported by Herndon et al.,143 which involved heating in a 
screw-cap vial (sealed tube) in the presence of toluene. However, since no base was added, 
the reaction did not go to completion.  
 
Model reactions were conducted for the structurally similar compound 94, the starting 
materials for which were more economical. A series of similar reactions outlined in 
Scheme 7 were attempted for the synthesis of 94, which brought us to the conclusion that 
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perhaps it was the synthetic routes and not the technique that was the undoing. Compound 
94 was synthesized by yet another general procedure reported by Herndon et al.143 and 
outlined in Scheme 8, which successfully resulted in compound 94. The reaction seemed to 
work better with the tricyclic compound 95.179 Nucleophilic attack of the amine seemed to 
occur best on the oxazoloquinazoline 95 with a minimum amount of solvent and when 
done neat.  
 
Thereafter, compound 85 was synthesized under high-pressure in a screw-cap vial (Scheme 
8), which gave better yields. It was difficult to dissolve the free base of 85 in an 
appropriate solvent for the preparation of its hydrochloride salt. A number of solvents such 
as EtOH, MeOH, MeCN, CHCl3, CH2Cl2 and ethyl acetate (EtOAc) were attempted. 
Finally, the free base was treated directly with conc. HCl to form the hydrochloride salt.  
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Scheme 8. Synthesis of compounds 85 and 94a 
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aReagent: (a) K2CO3, acetone, reflux, 2 h; (b) piperidine, screw-cap vial, 98 °C, 4 h; (c) 6-
fluoro-3-(piperidin-4-yl)benz[d]isoxazole, toluene, screw-cap vial, 100 °C, 44 h. 
 
 
Compounds 88 and 89 were synthesized from 6-fluoroindole (96) and compound 89 was 
synthesized from 88 by reduction of the double bond by hydrogenation with Pd/C (10%) 
under pressure and was submitted as a free base (Scheme 9). Compound 91 was 
synthesized from compounds 89 and 92, and is outlined in Scheme 9. After the 
optimization of the solvent, MeCN, for the Finkelstein reaction for compound 84, 
compound 91 was also synthesized by refluxing in MeCN. The yield, 9%, as for other 
Finkelstein reactions in this study, was low. 
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Scheme 9. Synthesis of compounds 88, 89 and 91a 
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aReagent: (a) 4-piperidone monohydrate hydrochloride, KOH, MeOH, reflux, 5 h; (b) (1) 
HCl/EtOH, MeOH, Pd/C (10%), Parr hydrogenator, 43 psi; (2) NaOH; (c) (1) compound 
92, MeCN, reflux, 45 h; (2) HCl/Et2O. 
 
 
A synthetic route for compound 90 has been reported171 and it was synthesized in a manner 
similar to that of 55, with the exception that the amino group of isonipecotic acid (75) was 
protected by converting it to the acetamide 97  (Scheme 10). Demethylation of a methoxy 
group in the Friedel-Crafts product 99 was due to excessive AlCl3 and dichloroethane 
(ClCH2CH2Cl). The oxime was converted to its acetate salt 100 and then reacted further 
with NaH to give the cyclized product 101. It has been suggested that the phenolic 
hydroxyl group of 100 effects a nucleophilic displacement reaction on the nitrogen of the 
oxime and the acetate salt makes the nitrogen of the oxime more conducive to this 
displacement reaction.171 The acetamide-protecting group was eventually removed by 
acidic hydrolysis. The synthesis is outlined in Scheme 10. 
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Scheme 10. Synthesis of compound 90a 
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aReagent: (1) Ac2O, EtOAc, 60 °C, 2 h; (2) room temperature, 24 h; (b) SOCl2, CH2Cl2, 
room temperature, 1.5 h; (c) 1,4-dimethoxybenzene, AlCl3, ClCH2CH2Cl, reflux, 20 h; (d) 
(1) hydroxylamine hydrochloride, NH4OAc, EtOH, reflux, 16 h; (2) Ac2O, 2 h, 60 °C; (e) 
NaH (toluene washed), DMF, room temperature, 48 h; (f) (1) conc. HCl, EtOH, reflux, 3 h.  
 
 
 
 
 
 
 
 
    
 99 
b. Functional activity studies:  
The functional activity assays of risperidone (3), ketanserin (42) and the hybrid compounds 
84 and 85 were performed in Dr. Logothetis’ laboratory by Jason Younkin and Amr 
Ellaithy, and were tested in the TEVC electrophysiological assay in the Xenopus laevis 
oocyte heterologous expression system. As discussed earlier, the TEVC assay measures the 
current at the GIRK4* channel associated with the 5-HT2A receptor (Figure 25).  
 
In the preliminary studies, at a dose of 10 µM, risperidone (3), ketanserin (42) and 
compound 84 antagonized the activity of 1 µM 5-HT and brought the Gαq-mediated 
activity of 5-HT down to about 20%, 15% and 21%, respectively. Paliperidone (10 µM) 
was also tested in the same assay system and it had an activity similar to risperidone by 
bringing the activity of 5-HT (1 µM) down to 20%.  However, compound 85 had relatively 
little effect on the activity of 5-HT (Figure 35).  
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Figure 35. The activity of risperidone, paliperidone, compounds 84 and 85, and ketanserin 
in the presence of 5-HT (figures provided by Jason Younkin and Amr Ellaithy). 
 
Compound 85 was thereafter tested by itself (in the absence of 5-HT) for Gαq-mediated 
activity and in the very preliminary studies showed an activity of around 20% compared to 
the activity of 5-HT (100%) (Figure 36). 
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Figure 36. The positive efficacy shown by ketanserin and compound 85 (figures provided 
by Jason Younkin and Amr Ellaithy).  
 
However, ketanserin, which is an established antagonist at 5-HT2A was shown to have a 
positive efficacy of 45% (Figure 36). This positive efficacy, as discussed previously for 
risperidone and its deconstructed analogs, could be due to the activity of the compound at 
the GIRK4* channel independent of the Gαq-mediated activity. This is under further 
investigation.  
 
c. Radioligand binding studies: 
The radioligand binding assay was conducted in Dr. Javier González-Maeso’s laboratory 
by Dr. José L. Moreno. As discussed earlier, these studies were performed in HEK293 
cells with [3H]-ketanserin (2 nM) as the radioligand. Non-specific binding was determined 
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in the presence of 10 µM methysergide and competition curves were generated and 
analyzed by nonlinear regression to derive the dissociation constants (Ki values). 
 
Risperidone (3), ketanserin (42) and their structural hybrids, compounds 84 and 85 were 
tested in this assay system. They bound with high affinity with Ki values of 5.22 ± 1.40, 
18.55 ± 1.78, 12.74 ± 1.50 and 0.96 ± 0.21 nM, respectively (Figure 37) (Table 5). 
Ki = 5.22 ± 1.40 nM
A B
Ki = 18.55 ± 1.78 nM
 
Ki = 12.74 ± 1.50 nM
Compound 84
C
Compound 85
Ki = 0.96 ± 0.21 nM
D
 
Figure 37. The binding affinity data for risperidone (A), ketanserin (B), compounds 84 
(C), and 85 (D) (figures provided by Dr. José L. Moreno). 
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Table 5. Biological activity of risperidone, ketanserin and their two hybrids. 
Compounds TEVC 
electrophysiology 
assay 
[% activity of 5-
HT in presence of 
the compounds] 
Radioligand 
binding assay, 
Ki ±SEM 
values (nM) 
N
N
O
CH3
N
ON
F
 
Risperidone (3) 
 
N
H
N
O
N
O
O
F
 
 
20 
 
 
 
 
 
 
 
15 
 
5.22 ± 1.40 
 
 
 
 
 
 
 
18.55 ± 1.78 
Ketanserin (42)   
 
N
N
O
CH3
N
O
F
 
84 
 
 
 
21 
 
 
12.74 ± 1.50 
N
H
N
O
N
O
ON
F
 
85 
 
 
85 
 
 
 
 
 
 
 
 
 
0.96 ± 0.21 
 
 
 
 
 
 
 
 
          *The biological assay data for 84 and 85 are from two experimental determinations. 
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3. Discussion: 
The functional activity data suggests that the structural hybrids of risperidone and 
ketanserin, compounds 84 and 85 have different activities at the receptor. Similar to 
risperidone, paliperidone and ketanserin, compound 84 seems to antagonize the activity of 
5-HT at the receptor, bringing it almost down to the baseline.  
 
Compound 85 did not seem to affect the activity of 5-HT to a great extent. Also, when 
tested by itself at the receptor, it gave a positive efficacy of ∼20% suggesting partial 
agonist activity. Also judging by its activity in the presence of 5-HT, it can be suggested 
that compound 85 shows potential to be a low potency partial agonist. However, dose 
response curves for both hybrids would be needed to confirm this.  In the same study 
(Figure 36), ketanserin gives an activity of 45%, which as discussed earlier, could be due 
to its activity at the GIRK4* channels. Although the same cannot be unequivocally said for 
the hybrid, testing compound 85 at the GIRK4* channel as a negative control would tell us 
how much of the activity is actually mediated through the Gαq pathway.  
 
Radioligand binding affinity data suggests that the two hybrids bind with high affinity at 
the 5-HT2A receptor. Compound 85, which has the left half of ketanserin and the right half 
of risperidone binds with the highest affinity, almost 5-, 13- and 19-fold higher than 
risperidone, 84 and ketanserin, respectively. The higher binding affinity of compound 85 
suggests that the right half of risperidone (which is common to both, 85 and risperidone), 
might be important for the binding affinity of risperidone. As the binding affinity of 85 is 
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∼5-fold higher than risperidone, the quinazolinedione moiety might be contributing 
towards enhancing the binding affinity.  
 
Compound 85, which contained the left half of ketanserin, binds with ∼19 times higher 
binding affinity compared to ketanserin. This suggests that the right half made certain 
interactions that reinforce its binding activity at the receptor. Herndon et al. had reported 
that the right half of ketanserin (4-fluorobenzoyl piperidine) was sufficient for binding at 
the receptor, while the left half (quinazolinedione) enhances the binding.143 The 
quinazolinedione could be strengthening the binding of compound 85 in a similar fashion, 
such that the binding affinity of 0.96 nM could be a combined effect of the left and the 
right halves of the compound.  
 
Compound 84 binds at the receptor with ∼2 times lower binding affinity than risperidone. 
As the binding affinity of the left half of risperidone has yet to be tested, we cannot make a 
strong argument regarding which structural half is responsible for its binding affinity. 
However, owing to its ∼13 fold lower binding affinity than compound 85, certain 
speculations can be made. First, it lacks certain structural features that contribute to the 
high binding affinity of 85 (0.96 nM). Second, the left half of 84 might not be contributing 
to its binding affinity, unlike the quinazolinedine moiety of compound 85, which seems to 
be bolstering the affinity (Herndon et al.).143 However, without the binding affinity of the 
left half of compound 84, it is difficult to draw conclusions about the effect the two 
structural halves have on the binding affinity of compound 85. 
    
 106 
C. MOLECULAR MODELING STUDIES:  
1. Approach 
Homology modeling and docking studies of risperidone and its deconstructed and 
elaborated analogs were conducted to examine their binding modes at the orthosteric 
binding site at the human 5-HT2A receptor. The different kinds of interactions with various 
amino acids at the receptor would give us an idea of the relative importance of the 
structural features making interactions. Moreover, we will gain a perspective into the 
relative binding modes of risperidone and ketanserin at the 5-HT2A receptor, and to identify 
any differences in their binding mode(s) (ligand receptor interactions), if they exist. 
Binding affinity and functional data will be compared with the results from the docking 
studies.  
 Furthermore, the possible role of the hydroxyl group of paliperidone was investigated, as 
was the role of the fluoro group of risperidone.  
 
As discussed earlier, the 5-HT2A receptor consists of seven transmembrane (TM) spanning 
helices180 with an extracellular N-terminus and an intracellular C-terminus (Figure 38). The 
human 5-HT2A protein subunit is about 52 kDa and is composed of 471 amino acids with 
124 amino acids forming the extracellular domain (ECD), 159 amino acids forming the 
TM, and 188 amino acids forming the intracellular domain (ICD).80 In addition, the protein 
also has a DRY motif (D172, R173, Y174), a NPxxY motif and a PDZ-motif along with 
two disulfide bridges formed by two sets of cysteine residues (i.e., C148 with C227 and 
C350 with C353).80,181,182 There is evidence that the DRY-motif is important for 
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maintaining receptor conformation, G-protein coupling/recognition and mutations of this 
conserved sequence has led to agonist-independent constitutive activity in certain GPCRs 
(rhodopsin, β2-adrenoceptors).183 The NPxxY motif is involved in stabilizing the active 
conformation of the receptor after activation and the PDZ domain can bind to PDZ 
proteins, which can influence almost all aspects of GPCR signaling, from ligand binding 
and G-protein coupling to downstream signaling events.184,185 
 
Figure 38. A model of the 5-HT2A receptor generated as a part of the current study. 
 
As the crystal structure of the 5-HT2A receptor has not yet been solved, we had to rely on 
homology with appropriate template proteins for a 3-dimensional view of the receptor. 
Initially, before the 3-dimensional structures of the known neurotransmitter receptors were 
resolved, graphical models of 5-HT2A receptors were built and analyzed using the structure 
of bacteriorhodopsin, which is not a GPCR, but a light-dependent proton pump.180 These 
models suffered from weak sequence homology and were highly dependent on 
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computationally intensive dynamics simulations.180 Later on, bovine rhodopsin replaced 
bacteriorhodopsin as the template.182,186 A breakthrough occurred in the field of homology 
modeling with the resolution of the crystal structure of the class A aminergic GPCR β2-
adrenoceptor in 2007. 5-HT2A receptors share a sequence homology of approximately 40% 
with β2-adrenoceptors (Table 6).186 
 
Table 6. Initial template choices for homology modeling of 5-HT receptors adapted from 
McRobb et al.186 
Receptor %Homology 
 Rhodopsin β2 adrenoceptors Adenosine A2A 
5-HT1B 23 41 35 
5-HT2A 22 40 30 
5-HT2B 22 40 30 
5-HT2C 23 42 30 
 
The 5-HT2 family of receptors shares a homology of about 70% with each other.80 In 2013 
the high-resolution crystal structure of the 5-HT2B receptor was solved (PDB ID: 4IB4, at 
2.7 Å) in complex with the β-arrestin signaling-biased agonist ergotamine.187 The P-I-F 
motif (located near the base of the ligand binding pocket, and involved in the 
conformational changes in GPCRs after activation),187 undergoes a number of 
conformational changes in response to an agonist, and showed a conformation similar to 
that of the inactive β2-adrenoceptor (PDB ID: 2RH1).187,188 As our present investigation is 
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focused on risperidone (with negative efficacy at the 5-HT2A receptor), which possesses a 
high affinity for the inactive state of the 5-HT2A receptor, and because of the high sequence 
homology of 70% between the two receptors, we used the crystal structure of the 5-HT2B 
receptor as a template.  
 
As a first step in building the homology models, the sequence of the target protein (5-HT2A 
receptor) was aligned with the corresponding residues from the template (5-HT2B receptor) 
using the CLUSTALX 2.1 program. As the sequence homology is quite high, most of the 
residues or the nature of the residues (such as hydrophobic or polar), matched (Figure 39). 
5"HT2B'
5"HT2A'
TM1$ TM2$
TM3$ TM4$
TM5$
TM6$ TM7$
 
Figure 39. Multiple sequence alignment between 5-HT2A and 5-HT2B receptors generated 
by the software CLUSTALX 2.1. 
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One hundred homology models were generated using the MODELLER v9.1 program; 
these were further refined by adding hydrogens and bridging the disulfide connections on 
SYBYL-X2.1. Ligands were docked using the programs GOLD Suite 5.2 and 5.3 and the 
the interactions of the solutions of ketanserin in the present study were compared with 
those reported in previously published homology models of 5-HT2A receptors and site-
directed mutagenesis data by our laboratory as well as other groups.189–193 The docked 
solutions were re-scored with the HINT (Hydropathic INTeractions) program, which is 
based on the experimental free energy information derived from log Po/w (the solvent 
partition co-efficient for 1-octanol/water).194 The HINT studies will quantify the different 
interactions each ligand makes with the receptor.  
 
2. Results and discussion:   
As a first step, the binding pocket of models generated as a part of our study was compared 
to previously published 5-HT2A receptor homology models. The model with the highest 
DOPE (Discrete Optimized Protein Energy) score as calculated by MODELLER was 
chosen for this comparison. According to previously reported homology models,189–193 the 
orthosteric binding pocket is located in the transmembrane region and is composed of 
residues belonging to TM3, TM5, TM6 and TM7, such as D155 and S159 (TM3), S239 
(TM5), W336, F339 and F340 (TM6), Y370 (TM7) and L228 and L229 (ECL2). Our 
model conformed to these reported results (Figure 40). 
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TM5 
TM6 
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D155 
S159 
S239 
F340 
F339 
Y370 
S240 
W367 
 
Figure 40. An energy minimized model from the current study with the binding pocket 
highlighted along with the residues constituting the binding pocket. 
 
An energy-minimized complex of ketanserin with the 5-HT2A receptor is depicted in Figure 
41.  In addition to the ionic interaction of the ammonium ion in the piperidine ring of 
ketanserin with the conserved aspartate residue (D155) in TM5, there were three additional 
hydrogen bonds: S159 (TM3) with the p-fluorobenzoyl carbonyl oxygen, S131 (TM2) with 
the N1 quinazolinedione nitrogen atom and S242 (TM5) with the p-fluorobenzoyl fluorine 
atom (Figure 41). Additionally, ketanserin was surrounded with a bed of hydrophobic 
residues: W151, V156 (TM3), F339, F340 (TM6), L228, L229 (ECL). 
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A 
D155 
Y370 
S159 
S239 
S242 
F339 
TM5 
TM6 
TM3 
TM2 
B 
S131 
TM5 
TM6 
TM7 
TM2 
ECL2 
C 
 
Figure 41. An energy-minimized ketanserin-receptor complex (A), interactions of 
ketanserin (purple) with amino acids forming the binding pocket (B), and hydrophobic 
residues, depicted as spheres, surrounding ketanserin (purple) in the binding pocket (C). 
 
The interactions made by ketanserin in our models were compared to those considered 
important in the literature models. The importance of these residues in the binding of 
ketanserin was previously assessed by site-directed mutagenesis studies (Table 7). As 
depicted in Figure 41 and Table 7, our model showed all the interactions reported to be 
important, and more.  
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Table 7. Site-directed mutagenesis data reported in the literature for the binding affinity of 
ketanserin.191,192,195–198 
Mutation TM domain Kd ± SEM 
(nM) 
Ki ± SEM (nM) Mutant/WT 
ratio 
Reference 
WT - - 0.5 ± 0.2 - 191 
D155A III - No binding  - 191 
D155N III - No binding - 191 
D155Q III - No binding - 191 
 
WT - - 0.8 ± 0.2 - 192 
D155N III - 60 ± 1 75 192 
 
WT - 0.98  - - 195 
W336A - 899  - 917.34 195 
W367L - No binding - - 195 
Y370A VII 18.4 - 18.77 195 
F365L - 3.9  - 3.97 195 
 
WT - 0.4  - - 196 
F339A VI 4.6  - 11 196 
F339L VI 9.8  - 24.5 196 
F339Y VI 2.8  - 7 196 
F340Y VI 29  - 72.5 196 
F340A VI 0.9  - 2.25 196 
F340L VI 0.3  - 0.75 196 
 
WT - 0.84  - - 197 
S159A III 1.1  - 1.30 197 
S159C III 0.66  - 0.78 197 
 
WT - - 2.3 - 198 
F243A - - 10.4  4.52 198 
F244A - - 6.7  2.91 198 
S239A V - 1.5 0.65 198 
 
Previously published models of the 5-HT2A receptor have described two possible binding 
modes for ketanserin: one with the p-fluorobenzoyl fluorine atom pointing towards TM5199 
and the second, with the fluorine atom pointing towards TM7182 (Figure 42). We observed 
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both binding modes; however, the GOLD score of the model with the fluorine atom 
pointing towards TM7 was low (51.32) compared to the GOLD score of the model with 
the fluorine atom pointing towards TM5 (63.62), making this pose possible, but unlikely. 
Also, the models reported in the literature were built using the crystal structure of bovine 
rhodopsin (PBD ID: 4X1H) as the template (sequence homology: <22%).182,199 A higher 
GOLD score coupled to a superior sequence homology of 70% with the template and 
adherence to interactions considered important by site-directed mutagenesis, validated our 
model (Figure 42). 
TM5 
TM6 
TM3 
TM7 
TM2 
B 
TM7 
TM3 
TM2 
TM6 
C 
D155 Y370 S159 
S239 
S242 
F339 
TM5 
TM6 
TM3 
TM2 
A 
S131 
 
Figure 42. The two binding modes of ketanserin: our model (A), literature models with the 
fluorine atom pointing towards TM5 (B),199 and pointing towards TM7 (C).182 
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Risperidone (3), paliperidone (7), ketanserin (42) and the analogs included in the 
deconstruction and elaboration of risperidone/paliperidone (i.e., compounds 55-58, 60, 84, 
85, and 90) were energy minimized before docking. Molecular docking was conducted 
using the scoring function within the docking program GOLD Suite 5.2 and the binding 
pocket was defined as being within a 10-Å radius surrounding the α-carbon atom of the 
D155 residue in TM3. The docking solutions were divided into clusters (the cluster 
docking script was provided by Dr. Philip D. Mosier) based on the binding poses. The 
clusters were analyzed and the models were evaluated for each ligand, based on the GOLD 
fitness scores, and interaction of the ammonium ion of the ligands with D155. For models 
selected (∼16 models for every ligand), based on the fitness score and the interactions, the 
solutions were merged with the models and energy-minimized using the Tripos Force field 
function in SYBYL-X2.1 to optimize the interactions. These models were further rescored 
by conducting HINT studies. The final model for each ligand was chosen based on the 
most optimal HINT score.  
 
a. Deconstruction of risperidone/paliperidone:  
The GOLD and HINT scores for the models chosen for risperidone, paliperidone and their 
deconstructed analogs (55-58) are summarized in Table 8. In the models chosen, 
risperidone (3), paliperidone (7) and all the deconstructed analogs had similar binding 
modes at the receptor, i.e., their 6-fluoro-3-(piperidin-4-yl)benz[d]isoxazole portion was 
oriented towards TM5 (see Figure 44).  
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Table 8. Risperidone and its deconstructed analogs: Ligands and the models chosen based 
on the GOLD and HINT scores. 
Ligand GOLD 
score 
Polar Hydrophobic Total 
HINT 
score 
D155 S159 S242 N363 
Risperidone 
(3) 
64.62 1523 1225 1204 737 374 82 22 
 
 
Paliperidone 
(7) 
58.19 1361 1026 873 732 368 67 210 
 
 
55 
 
48.73 1593 430 1366 1370 28 115 0 
56 
 
54.82 1250 1165 1093 740 379 87 6 
57 
 
53.99 1464 792 1445 682 258 55 352 
58 
 
46.56 1128 626 865 970 67 79 0 
 
A previously published model of the 5-HT2A receptor had described another mode of 
binding for risperidone where the 6-fluoro-3-(piperidin-4-yl)benz[d]isoxazole portion was 
oriented towards TM7200 (Figure 43) (similar to ketanserin, Figure 42).  
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Figure 43. The binding modes of risperidone: our model with the fluorine atom pointing 
towards TM5 (A), and literature model with the fluorine atom pointing towards TM7 
(B).200  
 
Similar to ketanserin, we observed both binding modes, however, the GOLD score of the 
model with the fluorine atom pointing towards TM7 was low (51.55) compared to the 
GOLD score of the model with the fluorine atom pointing towards TM5 (64.02). Also, the 
model reported in the literature was built using the crystal structure of β2 adrenergic 
receptor (PBD ID: 2RH1) as the template (sequence homology: 40%), while our model 
was built using the crystal structure of the 5-HT2B structure as the template (sequence 
homology: 70%).  
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TM6 
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TM5 
TM6 
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TM7 TM2 
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S159 
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S242 
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L229 
T160 
V156 
O1 N2 
B 
I206 
 
Figure 44. The binding orientation of risperidone (magenta), paliperidone (cyan) and their 
deconstructed analogs 55 (green), 56 (orange), 57 (yellow), and 58 (teal) at the 5-HT2A 
receptor (A), and their interactions with amino acids in the binding pocket (B).  
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Molecular modeling studies suggested that both halves of risperidone formed strong 
interactions at the receptor, while hydrophobic interactions predominated at the left half 
made up of the 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system; polar 
interactions seemed to dominate the front on the right half, consisting of the 6-fluoro-(3-
piperidinyl)benz[d]isoxazole moiety.  
 
All ligands formed an ionic bond with the conserved D155 (TM3), which is involved in 
anchoring the terminal amine moiety of tryptamines at the receptor.195 S159 (TM5) formed 
a bifurcated hydrogen bond with the 6-fluoro-(3-piperidinyl)benz[d]isoxazole O1 and N2 
atoms of all the deconstructed analogs (Figure 44). Bifurcated hydrogen bonds  (H-bond) 
occur when one hydrogen atom simultaneously forms H-bonds to two other H-bond 
acceptors.201 Compound 55 formed a second bifurcated H-bond interaction (O1 and N2 in 
6-fluorobenzisoxazole) with S242 (TM5) (Figure 45). From the radioligand binding data at 
the 5-HT2A receptor for the deconstructed analogs of risperidone (3) (Table 4), we can 
conclude that there is ∼15-fold difference in the binding affinity of risperidone and its 
smallest deconstructed analog 55. This suggests that even after removing the entire left 
half of risperidone (Ki = 5.22 nM), the compound 55 retained good binding affinity (Ki = 
75.75 nM). As seen from Figure 45, compound 55, although devoid of certain hydrophobic 
interactions made by the left half of risperidone, formed two bifurcated H-bonds (S159 and 
S242) that this could be supported by its retention of affinity at the receptor.  
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B 
 
Figure 45. The bifurcated H-bonds by compound 55 with S242 (TM5) in comparison to 
risperidone (magenta) (A), and the additional hydrophobic interactions made by compound 
58 (B). 
 
 
    
 121 
Strong hydrophobic interactions were observed between compound 58 and W151 (TM3) 
and V366 (TM7) that were lacking with 55 and the other deconstructed analogs (Figure 
45). Radioligand binding studies indicated that 58 has a high binding affinity                   
(Ki = 18.77 nM), and although it lacks certain structural features of risperidone, it binds 
with only ∼3-fold lower affinity than risperidone. Compounds 55 and 58 differ only in a 
single N-methyl group, but compound 58 binds with ∼4-fold higher affinity. The N-methyl 
group increased the binding affinity of 55 by ∼4-fold and the extra hydrophobic 
interactions made by 58 might be contributing.  
 
Functional data suggested that compound 57 enhanced the activity of 5-HT and could 
potentially behave as a superagonist or an ago-allosteric modulator. Its high binding 
affinity (Ki = 35.20 nM) indicated that it might exert at least part of its activity at the 
orthosteric site of the 5-HT2A receptor. Modeling studies showed that the compound 
lacking the carbonyl group 57 formed a strong hydrogen bond with N363 (TM7) (Table 8 
and Figure 46) with the ammonium ion in its second piperidine ring (risperidone has this 
nitrogen atom as a part of the 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring 
system). This suggests that 57 is capable of forming additional interactions at the receptor 
close to the binding pocket. Although it cannot be said with certainty at this moment, 
compound 57 might potentially be binding at two sites (orthosteric as well as a potential 
allosteric site) simultaneously. 
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N363 
A 
 
N363 
B 
 
Figure 46. The interaction of compound 57 (yellow) with N363 (TM7) compared to 
risperidone (magenta) (A), and a comparison of the binding pose of risperidone (magenta) 
and paliperidone (cyan) (B). 
 
Molecular modeling studies showed that the hydroxyl group of paliperidone (the only 
point of difference between risperidone and paliperidone) did not directly participate in 
hydrogen bonding (Figure 46). This could explain why the two compounds have almost 
identical binding affinities at the receptor as shown by literature (risperidone: Ki = 0.16 nM 
and paliperidone: Ki = 0.25 nM).202 
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b. Elaboration of risperidone/paliperidone:  
i. Comparison of the binding modes of risperidone and ketanserin:  
In order to gain insight into the functional and binding differences observed with 
risperidone (3) and ketanserin (42), we conducted a comparative study of their binding 
modes at the receptor and their respective molecular interactions with specific amino acids 
lining the binding pocket. Furthermore, we docked their structural hybrids, compounds 84 
and 85 to get a better insight into the two structural halves of risperidone and ketanserin. 
The GOLD scores and the HINT scores for the chosen models for risperidone, ketanserin 
and 84 and 85 are summarized in Table 9.  
 
Table 9. Risperidone, ketanserin and their structural hybrids: Ligands and the models 
chosen based on the GOLD and HINT scores 
Ligand GOLD 
score 
Polar Hydrophobic Total 
HINT 
score 
D155 S159 S242 
Risperidone 
(3) 
64.62 1523 1225 1204 737 374 82 
Ketanserin 
(42) 
63.62 1658 900 1112 724 374 169 
84 
 
61.16 1387 1054 1044 733 395 73 
85 
 
63.09 1547 870 1121 745 369 12 
 
 
All four ligands had a similar binding pose at the receptor and the hybrid compounds 84 
and 85 made the ionic interaction with D155 as discussed earlier with ketanserin and 
risperidone (Figure 47).  
    
 124 
 
D155 
Y370 
S159 
S239 
S242 
F339 
TM5 
TM6 
TM3 
TM2 
S131 
L229 
ECL2 
 
Figure 47. The similar binding pose of risperidone (magenta), ketanserin (purple), 
compounds 84 (gold) and 85 (dark green) at the receptor.  
 
There was a difference in the manner in which ketanserin (42) docked at the receptor 
compared to risperidone (3) and compounds 84 and 85. The right half of ketanserin (p-
fluorobenzoyl) was oriented upwards compared to the other ligands to form a stronger 
interaction with S242 from TM5 (Table 9) (Figure 48). 
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S242 
 
Figure 48. A snapshot of the differences in the orientation of the common p-fluorobenzoyl 
moiety of ketanserin (purple) and compound 84 (gold) at the receptor.  
 
Both the hybrid compounds have certain structural remnants of ketanserin – compound 84 
has the right half of ketanserin and compound 85 has the left half of ketanserin (Figure 32); 
however, both had a better overlap with risperidone in their docking solutions (Figure 49). 
In fact, the common quinazolinedione portion of ketanserin and compound 85 seemed to 
bind differently. The quinazolinedione ring of 85 seemed to rotate by 180° around the 
horizontal axis to overlap completely with the 6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-
one ring system of risperidone (Figure 49). Radioligand binding bolstered this observation, 
with compound 85 (Ki = 0.96 nM) having an almost identical binding affinity with 
risperidone (Ki = 5.22 nM). 
 
Additional hydrophobic interactions were observed between risperidone and the residues 
I135, I152, L229 (ECL2) and V366 on the receptor. These interactions, though absent in 
    
 126 
ketanserin, were present in both hybrid compounds, suggesting a preference of binding 
similar to risperidone rather than ketanserin.  
A 
 
B 
C 
 
Figure 49. The alignment of the hybrid compounds 84 (gold) and 85 (dark green) with 
risperidone (magenta) (A), differences in the orientation of the common quinazolinedione 
moiety of ketanserin (purple) and compound 85 (dark green) at the receptor (B), and the 
perfect alignment of the left halves of risperidone (magenta) and compounds 84 (gold) and 
85 (dark green) (C). 
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ii. Effect of substituents on the benzisoxazole ring:  
As discussed earlier, removal of the p-fluorobenzoyl fluorine atom decreased the binding 
affinity of certain deconstructed analogs of ketanserin (Figure 22).143 In our molecular 
modeling studies all the ligands seemed to dock orienting their fluoro substituent towards 
S242 (TM5). Furthermore, the HINT studies suggested the formation of a potential 
hydrogen bond between the fluorine atom and S242 for all compounds.  
 
Hence, we conducted molecular modeling studies on compounds 60 (lacking the fluoro 
group) and 90 (bearing a 5-OCH3 group) and compared their binding modes and molecular 
interactions with the fluoro substituent of compound 55 (Figure 50) to determine the 
importance of the fluoro substituent to examine the effect of substituents (or the absence of 
them) and the position of the substituents on the benzisoxazole ring, on the polar and 
hydrophobic interactions of the benzisoxazole ring system. 
H
N
ON
F
H
N
ON
55 60 H
N
ON
90 OCH3  
Figure 50. Structural comparison for the study of the effect of substituents on the three 
benzisoxazoles.  
 
The three compounds 55, 60, and 90 had a similar binding mode at the receptor (Figure 
51). Despite being structurally indistinguishable other than for the substituents, they did 
not align perfectly at the receptor and the source of the misalignment seemed to stem from 
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the interactions made by the substituents on the benzisoxazole ring or the lack of 
substituents (Figure 51).  
S242 
S159 
L229 
S239 
V156 
I152 
F339 
N343 
TM5 
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D155 
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Figure 51. The binding modes of the three benzisoxazoles, 55 (green), 60 (pink) and 90 
(gray) (A), and their molecular interactions with the orthosteric site amino acids (B). 
 
All three ligands formed the indispensible ionic interaction with D155 from TM3 and the 
bifurcated H-bond with S159 (with their 6-fluoro-(3-piperidinyl)benz[d]isoxazole O1 and 
N2 atoms). As discussed earlier for compound 55, S242 seemed to form a bifurcated H-
bond with compounds 60 and 90 as well. The desfluoro compound 60 seemed to be closer 
to S242 and made a stronger interaction with S242 (Table 10).  
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Table 10. Role of substituents and their position on the binding interaction of 
benzisoxazole ring: Ligands and the models chosen based on the GOLD and HINT scores 
Ligand GOLD 
score 
Polar Hydrophobic Total 
HINT 
score 
D155 L229 S239 S242 
55 
 
48.73 1593 430 1366 1370 26 33 115 
60 
 
46.76 1862 342 1463 1548 18 1 199 
90 
 
46.74 2022 638 1654 1300 121 0 113 
 
 
The difference in substituents was reflected in the interactions made by the three 
compounds and these were quantified by HINT studies (Table 10). Compound 55 formed a 
weak hydrogen bond with S239 from TM5, whereas compounds 60 and 90 did not form 
this interaction. The methoxy group of 90 made a strong hydrophobic interaction with 
L229 from ECL2, which was marginal for 55 and 60. The O atom of the methoxy group of 
90 also formed a weak hydrogen bond with N343 (TM6) and this interaction was lacking 
by both, 55 and 60.  
 
Radioligand binding data would be more conclusive regarding the role played by the 
presence (or absence) of substituents and on the position of the substituents on the 
benzisoxazole ring. Molecular modeling and HINT studies suggested some differences in 
their specific interactions. Although 5-methoxy compound 90 utilized more hydrophobic 
and hydrogen bonds than 55 and 60, the lack of substituents seemed to orient compound 60 
more towards S242 (TM5), compared to 55 and 90 (Figure 51).  
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CHAPTER V: CONCLUSION 
 
 
 
 
The primary intent of the current investigation was to study the structure of risperidone 
with respect to its inhibitory action at 5-HT2A receptors and to determine the minimum 
structural features of risperidone responsible for its antagonist activity. This was probed by 
the medicinal chemistry principles of deconstruction and elaboration. The current 
investigation also focused on the deconstruction of paliperidone (9-OH risperidone). 
Structurally, risperidone is a deconstructed analog of paliperidone.  
 
The systematically deconstructed analogs of risperidone (55-58) were tested for their 
functional activity in two assays, which gave differing results. Although the calcium 
imaging assay suggested that the compounds have antagonist activity, the more sensitive 
TEVC assay indicated that the compounds were low-efficacy partial agonists – with the 
exception of compound 57, which at a higher concentration of 50 µM seemed to possess 
activity greater than the endogenous ligand 5-HT. Compound 57 could either be a potential 
superagonist, an allosteric modulator or the compound might be activating the GIRK4* 
channels independent of the 5-HT2A receptor, or a combination of two or more of these 
actions. These results were subjected to further investigation by testing compound 57 at the 
GIRK4* channel in the presence and absence of the 5-HT2A receptor (see Appendix A). 
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The most striking feature of the functional activity data was the fact that in the TEVC 
assay compounds 55 and 58 had inhibitory activity comparable to that of risperidone, 
implying that the entire structure of risperidone might not be required for its antagonist 
activity. As such, this (coupled with our previously published data on 55164) suggest that 
the benzisoxazolylpiperidine moiety represents a pharmacophore for the 5-HT2A antagonist 
action (and binding) of risperidone-type agents. 
 
With speculation about the functional activity data in hand and speculations about the 
potential ‘superagonist’ or ‘ago-allosteric’ properties of compound 57 the compounds were 
tested in a radioligand binding assay to determine if the functional activity observed was 
due to their effect at 5-HT2A receptors. Risperidone and its deconstructed analogs bind with 
high affinity at the receptor, which suggested that compound 57 exerts at least part of its 
activity by binding at the orthosteric site of the receptor. 
 
The radioligand binding data of the deconstructed analogs suggested that the N-methyl 
compound 58 (Ki = 18.77 nM), which has the highest binding affinity among all the 
deconstructed analogs of risperidone (55-58), was comparable to risperidone (Ki = 5.22 
nM). This means that the entire structure of risperidone is not important for its affinity at 
the receptor, and that the 2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one 
ring system can be removed (along with the hydrophobic interactions it makes) and the 
hydrophobic interactions made by the free N-methyl group can substitute for those 
interactions. Molecular modeling studies showed that the N-methyl group of compound 58 
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forms certain hydrophobic interactions (V366 and W151) (Figure 45). These interactions 
were not exhibited by even the longer deconstructed analogs 56 and 57. 
 
The comparative study between risperidone (Ki = 5.22 nM) and ketanserin (Ki = 18.55 nM) 
brought out certain differences in the way risperidone and ketanserin bind at the receptor. 
Compound 85, which has the left half of ketanserin and the right half of risperidone had 
the highest affinity at the 5-HT2A receptor, almost 5-, 13-, and 19-fold higher than 
risperidone, 84 and ketanserin, respectively. This suggested that the interactions formed by 
85 are optimal for high binding affinity. One conclusion that can be drawn from the higher 
binding affinity of compound 85 is that the right half of risperidone might be important for 
its binding affinity at the 5-HT2A receptor. As 85 and risperidone differ in their left halves 
(85 has the quinazolinedione moiety), the quinazolinedione moiety of 85 might be 
contributing towards the binding affinity and enhancing it.  
 
Herndon et al.143 had previously reported that the left half of ketanserin, 2,4-
quinazolinedione, contributed to or enhanced the affinity of ketanserin and the 2,4-
quinazolinedione moiety by itself bound poorly at the receptor (Ki = 10,000 nM). It can be 
speculated from this information that the right half of compound 85 might be sufficient to 
maintain affinity at the receptor and the left half (the 2,4-quinazolinedione moiety) could 
be reinforcing the affinity. A comparison of the binding affinities of compounds 55 (Ki = 
75.75 nM), 85  (Ki = 0.96 nM) and risperidone (Ki = 5.22 nM) indicates that the 
quinazolinedione moiety might be a better contributor towards high binding affinity at      
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5-HT2A receptors than the 2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one 
ring system of risperidone.  
The functional activity data of the hybrid compounds suggested that compound 85 is a 
partial agonist at the 5-HT2A receptor. The observed efficacy could be due to its activity at 
GIRK4* entirely that masks the potential antagonist activity of the compound (thus 
making it a potential partial agonist; Figure 27) or a combination of the two (making it a 
low-efficacy partial agonist). However, with the binding affinity data in hand, if we 
consider the current efficacy as the Gαq-mediated activity at 5-HT2A receptors, compound 
85 shows potential to be a low-efficacy partial agonist. However, both its structural halves 
are composed of ligands (left half: ketanserin and right half: risperidone), which are known 
to be antagonists at the 5-HT2A receptor.  
 
According to previously published reports the quinazolinedione moiety can be a part of 
agonists, partial agonists or antagonists, depending upon the moiety attached to the other 
end (Figure 52). In fact, RH-34 (103) is known as a selective, potent partial agonist at 5-
HT2A receptors (Figure 52). 
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Figure 52. The range of efficacies (intrinsic activities) that the quinazolinedione moiety 
can be a part of. The intrinsic activity (i.a.) was measured using either rat tail artery (RTA) 
or rat jugular vein (RJV).203,204  
 
Thus the quinazolinedione moiety does not seem to influence the action of the compounds 
(Figure 52) and the action is likely determined by the moiety linked to it or the functional 
group on those moieties. The functional activity of compound 85, (which has the 2,4-
quinazolinedione moiety as its left half) could be influenced by its right half, which is 6-
fluoro-(3-piperidinyl)benz[d]isoxazole or compound 55. The functional activity data as it 
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currently stands, could imply that 85 is a low-efficacy partial agonist or it is an antagonist 
(if the efficacy shown is due to activity at GIRK4*). We can speculate the same about 
compound 55. If 85 and 55 are antagonists (Iwamura et al.164 had reported 55 to be an 
antagonist), it suggests that the quinazolinedione moiety in 85, as portrayed for other 
quinazolinedione-containing compounds (Figure 52), might not influence its action and the 
activity could be due to the 6-fluoro-(3-piperidinyl)benz[d]isoxazole moiety attached to it.  
 
Compound 84 shows a functional activity similar to risperidone in the TEVC assay system 
(Figure 35). However, as the binding affinity and functional activity of 2-methyl-6,7,8,9-
tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system is forthcoming, we cannot 
conclude on the structural half contributing to its activity. However, there is literature 
evidence that the 6-fluoro-(3-piperidinyl)benz[d]isoxazole moiety is a more potent 
antagonist at 5-HT2A receptors than the 4-fluorobenzoylpiperidine moiety. As the current 
functional data (Figure 35) indicates that 84 antagonizes the 5-HT mediated activity more 
potently than 85, this suggests that perhaps the left half of 84 (2-methyl-6,7,8,9-tetrahydro-
4H-pyrido[1,2-a]pyrimidin-4-one ring system) could be influencing the activity of this 
compound.  
 
Forthcoming binding affinity data and functional activity studies will guide us as regards 
making a conclusive argument about the precise role of various structural elements of 
risperidone in its activity at the receptor. However, with the biological data currently in 
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hand, it does seem that the entire intact structure of risperidone might not be required for 
its activity and its affinity at 5-HT2A receptors.  
 
The ability of compound 55 to crosstalk in a system co-expressing 5-HT2A receptors and 
mGlu2 receptors is promising in terms of the fact that established inverse agonists at 5-
HT2A receptors such as clozapine and risperidone also exhibit this crosstalk. It would mean 
that this portion of risperidone, could be sufficient for its inverse agonist activity at 5-HT2A 
receptors. 
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CHAPTER VI: EXPERIMENTALS 
 
 
 
 
A. Synthesis: 
Melting points (mp) were measured on the Thomas Hoover melting point apparatus and 
are uncorrected. Proton NMR (1H NMR) spectra were recorded with a Bruker ARX 400 
MHz spectrometer using trimethylsilane (TMS) as an internal standard, with peak 
positions indicated by parts per million (δ). Infrared spectroscopy was conducted on a 
Thermo Nicolet iS10 FT-IR. Electrospray ionization-mass spectrometry studies were 
conducted using a Waters Acquity TDQ (tandem quadrupole) spectrometer in positive ion 
mode. Elemental analyses (CHN) determined the purity of the compounds and was 
performed by Altantic Microlab Inc. and the obtained values were within 0.4% of 
theoretical values. Reactions were monitored by thin-layer chromatography (TLC) on 
silica gel GHLF plates (250 µm, 2.5 x 10 cm; Analtech Inc. Newark, DE), and flash 
chromatography was performed on a CombiFlash Companion/TS (Teledyne Isco Inc. 
Lincoln, NE) using packed silica gel (Silica Gel 230-400 mesh) columns (RediSep Rf 
Normal-phase Silica Flash Column, Teledyne Isco Inc., Lincoln, NE).  
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6-Fluoro-3-(piperidin-4-yl)benz[d]isoxazole hydrochloride (55). 
Compound 80 (0.10 g, 0.40 mmol) was added to a stirred solution of HCl (12 N, 0.14 mL) 
and EtOH (7.0 mL) under an N2 atmosphere. The reaction mixture was heated at reflux for 
3 h and allowed to stand at room temperature for 48 h to afford a buff-colored solid that 
was recrystallized from EtOH/H2O to yield 0.02 g (18%) of compound 55 as a white solid: 
mp 302-304 °C (lit.171 302-306 °C) 1H (DMSO-d6): 2.07-2.52 (m, 6H, CH2), 3.09 (s, 2H, 
CH2), 3.34-3.58 (m, 1H, CH), 7.33 -7.39 (m, 1H, ArH), 7.73-7.76 (m, 1H, ArH), 8.11-8.14 
(m, 1H, ArH), 9.03 (br s, 1H, NH+). 
 
4-(4-(6-Fluorobenz[d]isoxazol-3-yl)piperidin-1-yl)-1-(piperidin-1-yl)butan-1-one 
hydrochloride (56). 
Compound 67 (0.22 g, 1.14 mmol) and 6-fluoro-3-(piperidin-4-yl)benz[d]isoxazole (0.25 
g, 1.14 mmol) were added to a stirred solution of K2CO3 (0.31 g, 2.26 mmol) and KI (few 
crystals) in anhydrous MeCN (5 mL). The reaction mixture was allowed to stir in a screw-
cap vial at 88 °C for 16 h. The solvent was evaporated under reduced pressure; the residue 
was suspended in H2O and extracted with CHCl3 (3 x 15 mL). The combined organic 
portions were washed with H2O (3 x 10 mL), dried (Na2SO4) and evaporated under 
reduced pressure to yield a buff-colored solid. The solid was dissolved in EtOH (5 mL) 
and the solution was cooled to 0 °C. A saturated solution of gaseous HCl in Et2O (2 mL) 
was added and the mixture was allowed to stand at room temperature for 3 h. The solvent 
was evaporated to yield a white solid that was recrystallized from EtOH to yield 0.01 g 
(3%) of compound 56 as a tan-colored solid: mp 216-218 °C (This compound was 
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previously prepared in our laboratory as RHV-023 but has not been reported 207-210 °C) 
1H (DMSO-d6): 1.43-1.69 (m, 4H, CH2), 1.82-2.10 (m, 6H, CH2), 2.21-2.24 (m, 2H, CH2), 
2.82-2.88 (m, 2H, CH2), 2.82-2.88 (m, 1H, CH), 3.23-3.26 (m, 2H, CH2), 3.40-3.52 (m, 
2H, CH2), 3.63-3.66 (m, 2H, CH2), 3.98-4.02 (m, 2H, CH2), 4.48-4.51 (m, 2H, CH2), 7.29-
7.38 (m, 1H, ArH), 7.70-7.76 (m, 1H, ArH), 8.05-8.18 (m, 1H, ArH), 10.17 (br s, 1H, 
NH+) Anal Calcd for (C21H28FN3O2·HCl·0.5H2O) C, 60.21; H, 7.02; N, 9.77. Found: C, 
60.32; H, 7.22; N, 10.03. 
 
6-Fluoro-3-(1-(4-(piperidin-1-yl)butyl)piperidin-4-yl)benz[d]isoxazole (57). 
A 1M solution of BH3 in THF (1.41 mL) was added to a stirred solution of the free base of 
4-(4-(6-fluorobenz[d]isoxazol-3-yl)piperidin-1-yl)-1-(piperidin-1-yl)butan-1-one (56) 
(0.13 g, 0.35 mmol) in anhydrous THF (4 mL) at 0 °C (ice-bath). The reaction mixture was 
allowed to warm to room temperature and stirring was continued for 10 h. The reaction 
mixture was carefully quenched with 6 M aqueous HCl (0.40 mL, vigorous bubbling 
occured) and heated at reflux for 1 h. The mixture was allowed to cool to room 
temperature and basified with 1N aqueous NaOH (2 mL). H2O (10 mL) was added and the 
aqueous layer was extracted with EtOAc (3 x 15 mL). The organic portion was combined, 
dried (Na2SO4), and solvent was removed under reduced pressure to give an oily residue. 
The oily residue was dissolved in absolute EtOH and HCl-anhydrous Et2O was added to 
afford a solid. Recrystallization from absolute EtOH/anhydrous Et2O gave 0.04 g (26%) of 
57 as yellow crystals: mp 270-273 °C; 1H-NMR (DMSO-d6: salt) δ 1.37 (m, 1H, CH2), 
1.68-1.78 (m, 10H, CH2), 2.17-2.20 (m, 2H, CH2), 2.38-2.53 (m, 2H, CH2), 2.83 (m, 2H, 
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CH2), 3.01-3.10 (m, 7H, CH, CH2), 3.36-3.46 (m, 1H, CH2), 3.58-3.61 (m, 2H, CH2), 7.32 
(td, J = 9.1,2.0 Hz, 1H, ArH), 7.71 (dd, J = 9.0, 1.9 Hz, 1H, ArH), 8.25 (dd, J = 8.6, 5.4 
Hz, 1H, ArH), 10.33 (br s, 1H, NH), 11.06 (br s, 1H, NH) Anal. Calcd 
(C21H30FN3O·2HCl·0.25H2O) C, 57.73; H, 7.50; N, 9.62. Found: C, 57.36; H, 7.21; N, 
9.30. 
 
6-Fluoro-3-(1-methylpiperidin-4-yl)benz[d]isoxazole hydrochloride (58). 
6-Fluoro-3-(piperidin-4-yl)benz[d]isoxazole (the free base of compound 55) (0.20 g, 0.90 
mmol) was added to a stirred solution of HCOOH (0.2 mL, 5.45 mmol) and HCHO (0.2 
mL, 5.45 mmol) in EtOH under an N2 atmosphere. The reaction mixture was heated at 
reflux for 10 h and the solvent was evaporated to yield a white-colored solid. The solid was 
dissolved in EtOH (5 mL) and cooled to 0 °C. A saturated solution of gaseous HCl in Et2O 
(2 mL) was added and the mixture was allowed to stand at room temperature for 3 h. The 
solvent was evaporated to yield a white solid that was recrystallized from EtOH to yield 
0.01 g (4%) of 58 as a white solid: mp 218-220 °C (This compound was previously 
prepared in our laboratory as RHV-008 but has not been reported 225-227 °C) 1H (DMSO-
d6): 2.20-2.25 (m, 4H, CH2), 2.20-2.23 (m, 1H, CH), 2.80 (s, 3H, CH3), 3.09-3.19 (m, 2H, 
CH2), 3.53-3.56 (m, 2H, CH2), 7.33-7.38 (m, 1H, ArH), 7.73-7.75 (dd, J = 2, 8 Hz, 1H, 
ArH), 8.15-8.18 (m, 1H, ArH), 10.64 (br, s, 1H, NH+) Anal Calcd for 
(C13H15FN2O·HCl·0.5H2O) C, 55.82; H, 6.13; N, 10.01. Found: C, 55.50; H, 6.08; N, 
9.69.0 
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(±)4-(4-(6-Fluorobenz[d]isoxazol-3-yl)piperidin-1-yl)-1-(3-hydroxypiperidin-1-yl) 
butan-1-one hydrogen oxalate  (59). 
Compound 75 (0.37 g, 1.82 mmol) and 6-fluoro-3-(piperidin-4-yl)benz[d]isoxazole (the 
free base of compound 55) (0.40 g, 1.82 mmol) were added to a stirred solution of K2CO3 
(0.50 g, 3.63 mmol) and KI (few crystals) in MeCN (4 mL). The reaction mixture was 
allowed to stir in a screw-cap vial for 45 h at 88 °C, cooled to room temperature and the 
excess solvent was evaporated under reduced pressure to afford a white solid. The residue 
was suspended in H2O (10 mL) and extracted with CHCl3 (3 x 25 mL). The combined 
organic portion was washed with H2O (3 x 15 mL), brine (5 mL), dried (Na2SO4) and 
evaporated under reduced pressure to yield a pale yellow-colored oil, which was purified 
by flash chromatography (silica gel; CHCl3/MeOH; 9.5:0.5) to afford a colorless oil. The 
oil was dissolved in EtOAc (5 mL) and cooled to 0 °C. A saturated solution of oxalic acid 
(1.2 eq) in Et2O was added and the reaction mixture was allowed to stir at room 
temperature overnight. The precipitate was collected by filtration to yield a white solid, 
which upon recrystallization from EtOH/Et2O afforded 0.03 g (4%) of 59 as a white solid: 
mp 182-184 °C. 1H NMR (DMSO-d6): 1.31-1.41 (m, 2H, CH2), 1.65-1.86 (m, 4H, CH2), 
2.12-2.24 (m, 4H, CH2), 2.40-2.70 (m, 2H, CH2), 2.40-2.70 (m, 1H, CH), 3.00-3.18 (m, 
6H, CH2), 3.33-3.49 (m, 6H, CH2), 7.30-7.33 (t, J = 12 Hz, 1H, ArH), 7.70-7.72 (d, J = 8 
Hz, 1H, 1ArH), 7.89-8.19 (m, 1H, ArH) Anal Calcd for (C21H28FN3O3·C2H2O4) C, 57.61; 
H, 6.31; N, 8.76. Found: C, 57.57; H, 6.26; N, 8.58. MS calculated: [M+H]+ = 390.2187, 
MS found: [M+H]+ = 390.2195. 
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3-(Piperidin-4-yl)benz[d]isoxazole hydrochloride (60). 
A solution of KOH (85%) was added to a stirred solution of compound 83 (0.14 g, 0.45 
mmol) in absolute EtOH (3 mL) under an N2 atmosphere. The reaction mixture was heated 
at reflux for 48 h and cooled to room temperature. The solvent was removed under reduced 
pressure and the aqueous mixture was extracted with EtOAc (3 x 15 mL). The combined 
organic portion was dried (Na2SO4), and evaporated under reduced pressure to yield a 
brown-colored oil. The oil was dissolved in absolute EtOH (2 mL) and cooled to 0 °C. A 
saturated solution of gaseous HCl in Et2O (2 mL) was added and the reaction mixture was 
allowed to stir at room temperature overnight. The precipitate was collected by filtration to 
yield a buff-colored solid, which upon recrystallization from MeOH-Et2O afforded 0.02 g 
(20%) of 60 as a white solid: mp 304-306 °C (lit.171 313-315 °C) 1H NMR (DMSO-d6): 
2.18-2.19 (m, 4H, CH2), 2.18-2.19 (m, 1H, CH) 3.10-3.17 (m, 2H, CH2), 3.38-3.47 (m, 2H, 
CH2), 7.40-7.44 (t, J = 8 Hz, 1H, ArH), 7.67-7.69 (m, 1H, ArH), 7.74-7.76 (m, 1H, ArH), 
8.07-8.09 (d, J = 8 Hz, 1H, ArH), 9.15 (s, 1H, NH, D2O ex). 
 
3-(1-Methylpiperidin-4-yl)benz[d]isoxazole hydrochloride (61). 
A solution of KOH (85%) was added to a stirred solution of compound 82 (0.20 g, 0.78 
mmol) and hydroxylamine hydrochloride (0.11 g, 1.67 mmol) in ethoxyethanol (3 mL)-
H2O (2 mL) under an N2 atmosphere. The reaction mixture was heated at reflux for 6 h, 
cooled to room temperature, quenched by addition of ice-H2O (50 mL) and extracted with 
Et2O (3 x 40 mL). The combined organic portion was washed with H2O (3 x 20 mL), brine 
(5 mL), dried  (Na2SO4) and evaporated to yield an orange-colored oil. The oil was 
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dissolved in EtOH (2 mL) and cooled to 0 °C. A saturated solution of gaseous HCl in Et2O 
(2 mL) was added to yield a white solid, which upon recrystallization from EtOH/Et2O 
afforded 0.04 g (23%) of 61 as a white solid: mp 248-250 °C (lit.171 250-252 °C) 1H NMR 
(DMSO-d6): 2.25-2.35 (m, 4H, CH2), 2.25-2.35 (m, 1H, CH) 2.73-2.88 (m, 3H, CH3), 
3.09-3.25 (m, 2H, CH2), 3.43-3.62 (m, 2H, CH2), 7.40-7.44 (t, J = 8 Hz, 1H, ArH), 7.65-
7.69 (m, 1H, ArH), 7.74-7.76 (m, 1H, ArH), 8.08-8.21 (m, 1H, ArH), 10.95 (s, 1H, NH, 
D2O ex). 
 
4-Chloro-1-(piperidin-1-yl)butan-1-one (67). 
Piperidine (68) (1.2 mL, 11.54 mmol) was added in a dropwise manner to a stirred solution 
of Et3N (1.2 mL, 11.54 mmol) in CH2Cl2 (25 mL) and the reaction micture was cooled to    
0 °C under an N2 atmosphere. A solution of 4-chlorobutyryl chloride (1.5 mL, 11.74 
mmol) in CH2Cl2 (5 mL) was added and the reaction mixture was allowed to stir at room 
temperature for 75 h and washed with H2O (2 x 25 mL). The organic portion was dried 
(Na2SO4) and evaporated under reduced pressure to yield a yellow-colored oil, which was 
purified by vacuum distillation to yield 1.00 g (45%) of 67 as a pale yellow-colored oil: bp 
103 °C at 0.02 psi.  
 
(±)4-Chloro-1-(3-hydroxypiperidin-1-yl)butan-1-one (74). 
A solution of 4-chlorobutyryl chloride (1.39 g, 9.88 mmol) in CH2Cl2 (20 mL) was added 
in a dropwise manner to a solution of (±)3-hydroxypiperidine (69) (1.00 g, 9.88 mmol) and 
Et3N (1.01 g, 9.98 mmol) in anhydrous CH2Cl2 (25 mL). The reaction mixture was allowed 
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to stir at room temperature for 16 h, quenched by addition of H2O (20 mL), and extracted 
with CH2Cl2 (3 x 15 mL). The combined organic portion was washed with H2O (3 x 20 
mL), brine (5 mL), dried (Na2SO4) and evaporated under reduced pressure to yield a 
yellow-colored oil, which was purified by flash chromatography (silica gel; CHCl3/MeOH; 
9.5:5) to afford 0.65 g (32%) of 74 as a colorless oil, which was used without further 
characterization in the preparation of compound 59.  
 
N-Formylpiperidine-4-carboxylic acid (76). 
A stirred solution of HCOOH (15 mL, 371.63 mmol) and Ac2O (35 mL, 371.63 mmol) 
was heated at 60 °C for 1 h and cooled to 0 °C (ice-bath). Isonipecotic acid (75) (8.00 g, 
61.93 mmol) was added and the reaction mixture was allowed to stir at room temperature 
for 16 h. The solvent was removed by vacuum distillation to yield a white solid that was 
recrystallized from i-PrOH to yield 6.00 g of 76 (66%) as a white solid: mp 136-138 °C 
(lit.171 136-138 °C).  
 
N-Formylpiperidine-4-carboxylic acid chloride (77). 
In a 3-neck flask, SOCl2 (4.50 mL, 6.37 mmol) was added in a dropwise manner to a 
stirred solution of compound 76 (5.00 g, 3.18 mmol) in DMF (0.6 mL) under an N2 
atmosphere and cooled to 0 °C (ice-bath). The reaction mixture was allowed to stir at room 
temperature for 6 h. SOCl2 was evaporated under reduced pressure to afford 5.00 g (90%) 
of 1-formylpiperidine-4-carboxylic acid chloride (77) as a yellow-colored oil, which was 
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verified spectrally and used without further characterization in the preparation of 
compound 78.  
 
N-Formyl-4-(2,4-difluorobenzoyl)piperidine (78). 
In a 3-neck flask, AlCl3 (5.70 g, 4.27 mmol) was added to a stirred solution of compound 
77 (5.00 g, 2.85 mmol) in 1,3-difluorobenzene (18 mL) and ClCH2CH2Cl (5 mL) under an 
N2 atmosphere and the reaction mixture was heated at reflux for 45 h. The reaction mixture 
was cooled to room temperature, quenched by the careful addition of ice/H2O (50 mL) and 
extracted with CHCl3 (3 x 50 mL). The combined organic portion was washed with H2O (3 
x 50 mL), brine (5 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 
3.00 g of a brown-colored oil, which was purified by column chromatography (silica gel; 
hexanes/EtOAc; 0.4:0.6) to afford 0.75 g of a colorless oil which, when triturated with 
petroleum ether, afforded 0.75 g (8%) of 78 as a white solid: mp 60-62 °C (lit.171 64-66 
°C).  
 
N-Formyl-4-((2,4-difluorophenyl)(hydroxyimino)methyl)piperidine (79). 
In a 3-neck flask, compound 78 (0.50 g, 1.97 mmol) was added to a stirred solution of 
hydroxylamine hydrochloride (0.41 g, 5.91 mmol) in EtOH (10 mL) under an N2 
atmosphere. A solution of NaOH (0.24 g, 6.00 mmol) in H2O (1.5 mL) was added and the 
reaction mixture was heated at reflux for 96 h. The reaction mixture was allowed to cool to 
room temperature and filtered. The filtrate was evaporated under reduced pressure to yield 
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a yellow-colored solid that was recrystallized from H2O to yield 0.42 g of 79 (79%) as a 
white solid: mp 178-180 °C (lit.171 182-184 °C). 
 
N-Formyl-4-(6-fluorobenz[d]isoxazol-3-yl)piperidine (80). 
Toluene washed NaH (0.06 g, 2.50 mmol) was added to a stirred solution of compound 79 
(0.20 g, 0.75 mmol) in anhydrous DMF (10 mL) and the stirred reaction mixture was 
heated at 75 °C for 4 h. The reaction mixture was allowed to stir at room temperature for 
48 h, quenched with H2O (25 mL) and extracted with EtOAc (3 x 20 mL). The combined 
organic portion was washed with H2O (3 x 20 mL), brine (5 mL), dried (Na2SO4), and 
evaporated under reduced pressure to yield 0.12 g of 80 (67%) as an orange oil. The 
structure was verified spectrally and used crude in the preparation of compound 55. 1H 
(CDCl3-d1): 1.80-1.89(m, 2H, CH2), 1.90-2.14(m, 2H, CH2), 2.45(s, 2H, CH2), 3.23-
3.37(m, 2H, CH2), 3.74-3.77 (m, 1H, CH), 4.36-4.39(m, 1H, CHO), 6.99-7.02 (m, 1H, 
ArH), 7.54-7.57 (m, 1H, ArH), 7.99-8.08 (m, 1H, ArH). 
 
(2-Fluorophenyl)(1-methylpiperidin-4-yl)methanone (82). 
In a 3-neck flask, 4-chloro-N-methylpiperidine (81) (1 g, 7.48 mmol) in anhydrous THF (3 
mL) was added in a dropwise manner to a stirred mixture of Mg (0.23 g, 9.51 mmol) in 
anhydrous THF (1 mL) and bromoethane (few drops) under an N2 atmosphere and the 
reaction was initiated by a warm H2O bath. After complete addition of 4-chloro-N-
methylpiperidine (81), the reaction mixture was heated at reflux for 1 h, cooled to room 
temperature and 2-fluorobenzonitrile (0.91 g, 7.48 mmol) in anhydrous THF (2 mL) was 
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added. The reaction was heated at reflux for 3 h, the reaction mixture was allowed to stir at 
room temperature for 36 h and quenched by addition of NH4Cl (2.93 g in 10 mL H2O). The 
reaction mixture was heated on a H2O bath for 2 h, cooled to room temperature and 
extracted with Et2O (3 x 20 mL). The combined organic portion was washed with H2O (3 x 
15 mL), brine (5 mL), dried  (Na2SO4) and evaporated to yield a brown-colored oil, which 
was purified by column chromatography (silica gel; CHCl3:MeOH: 9.2:0.8) to yield a 
brown-colored oil. The oil was dissolved in EtOH (5 mL) and cooled to 0 °C. A saturated 
solution of gaseous HCl in Et2O (2 mL) was added to yield a orange-colored solid, which 
was allowed to stir overnight with Et2O to yield 0.22 g (12%) of 82 as an orange solid: mp 
162-166 °C (lit.171 167-169 °C).  
 
Phenyl 4-(benz[d]isoxazol-3-yl)piperidine-1-carboxylate (83). 
An aqueous solution of compound 61 (0.23 g, 0.91 mmol) was basified with NaOH (1M, 
to pH 9) and extracted with toluene (4 mL). The organic portion was dried (Na2SO4), 
filtered and added to a stirred solution of phenyl chloroformate under an N2 atmosphere. 
The stirred reaction mixture was heated at reflux for 22 h, cooled to room temperature and 
filtered. The filtrate was evaporated under reduced pressure to yield a yellow-colored oil. 
The oil was dissolved in Et2O and petroleum ether was added to afford 0.15 g (52%) 
compound 83 as a buff solid: mp 91-92 °C (lit.171 96-98 °C). 
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3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,4(1H,3H)- 
quinazolinedione hydrochloride (85). 
Compound 95 (0.15 g, 0.79 mmol) was added to a stirred solution of 6-fluoro-3-(piperidin-
4-yl)benz[d]isoxazole (the free base of compound 55) (0.17 g, 0.79 mmol) in anhydrous 
toluene (3.6 mL). The reaction mixture was allowed to stir in a screw-cap vial for 44 h at 
100 °C. The excess toluene was removed under reduced pressure to yield a white-colored 
solid. The solid was dissolved in HCl (12 N) and cooled to 0 °C. The solvent was removed 
under reduced pressure to yield a white solid that was recrystallized from EtOH/H2O to 
yield 0.05 g (27%) of 85 as a white solid: mp 268-270 °C. 1H NMR (DMSO-d6):  2.15-
2.22 (m, 2H, CH2), 2.30-2.34 (m, 3H, CH2), 3.17-3.23 (m, 2H, CH2), 3.46-3.50 (m, 3H, 
CH2), 3.87-3.90 (m, 2H, CH2), 4.32-4.33 (m, 2H, CH2), 7.23-7.25 (d, J = 8 Hz, 2H, ArH), 
7.37-7.38 (d, J = 4 Hz, 1H, ArH), 7.69-7.74 (m, 2H, ArH), 7.97-7.99 (d, J = 8 Hz, 1H, 
ArH), 8.11-8.14 (dd, J = 4, 8 Hz, 1H, ArH), 9.81 (br, s, 1H, NH+, D2O ex) Anal Calcd for 
(C22H21FN4O3·HCl) C, 59.39; H, 4.98; N, 12.59. Found: C, 59.33; H, 5.14; N, 12.52.  
 
4-(6-Fluoro-[1H]-indol-3yl)-1,2,3,6-tetrahydropyridine hydrogen oxalate  (88). 
6-Fluoroindole (96) (0.25 g, 1.85 mmol) was added to a stirred solution of 4-piperidone 
monohydrate hydrochloride (0.72 g, 4.70 mmol) and KOH (0.55 g, 9.82 mmol) in 
anhydrous MeOH (6 mL) under an N2 atmosphere. The stirred reaction mixture was heated 
at reflux for 5 h, quenched by addition of H2O (25 mL) and allowed to stir at room 
temperature overnight. The precipitate was collected by filtration, washed with H2O to 
yield 0.20 g of a yellow-colored solid. The solid was dissolved in anhydrous MeOH (3 
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mL) and the solution was cooled to 0 °C. A solution of oxalic acid (1 equivalent) in MeOH 
was added and the reaction mixture was allowed to stir at room temperature overnight to 
yield a yellow-colored solid, which upon recrystallization from EtOH/H2O afforded 0.03 g 
(43%) of 88 as a yellow solid: mp 224 °C. 1H NMR (DMSO-d6): 2.61 (s, 2H, CH2), 3.20-
3.23 (t, J = 4, 2H, CH2), 3.66 (s, 2H, CH2), 6.16 (s, 1H, CH), 6.89-6.94 (td, J = 4, 8, 1H, 
ArH), 7.16-7.19 (dd, J = 12 Hz, 1H, ArH), 7.46-7.47 (d, J = 4 Hz, 1H, ArH), 7.79-7.83 (m, 
1H, ArH), 11.27 ( s, 1H, NH+, D2O ex) Anal. Calcd for (C13H13N2F·0.5C2H2O4·0.25H2O) 
C, 63.26; H, 5.49; N, 10.54. Found: C, 63.05; H, 5.43; N, 10.16.  
 
6-Fluoro-3-(piperidin-4-yl)-1H-indole (89). 
A saturated solution of gaseous HCl in EtOH (12 mL) was added to a stirred solution of 
the free base of compound 88 (0.12 g, 2.312 mmol) in MeOH (12 mL). 10% Pd/C (0.018 
g) was added and the reaction mixture was reduced in a Parr hydrogenator at 44 psi for 20 
h. The reaction mixture was filtered and the filtrate was evaporated under reduced 
pressure. The residue was dissolved in H2O (10 mL), the solution was basified with NaOH 
(1N, to pH 8) and extracted with EtOAc (3 x 20 mL). The combined organic portion was 
washed with H2O (3 x 10 mL), dried (Na2SO4) and evaporated under reduced pressure to 
give a yellow-colored solid, which upon recrystallization from EtOH afforded 0.02 g 
(15%) of 89 as a pale yellow-colored solid: mp 216-218 °C (lit.205 mp 214-216 °C) 1H 
NMR (DMSO-d6): 1.54-1.65 (m, 2H, CH2), 1.87-1.89 (m, 2H, CH2), 2.66-2.73 (m, 2H, 
CH2), 2.81-2.89 (m, 1H, CH), 3.07 (m, 2H, CH2), 6.79-6.84 (m, 1H, ArH), 7.06-7.12 (m, 
2H, ArH), 7.53-7.57 (m, 1H, ArH), 10.90 (s, 1H, NH+, D2O ex). 
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5-Methoxy-3-(piperidin-4-yl)benz[d]isoxazole hydrochloride (90). 
Compound 101 (0.089 g, 0.55 mmol) was added to a stirred solution of HCl (12 N, 0.10 
mL) and EtOH (5.0 mL) under an N2 atmosphere. The reaction mixture was heated at 
reflux for 3 h and allowed to stand at room temperature for 48 h to afford a brown-color 
oil. The oil was dissolved in EtOAc (2 mL) and the solution was cooled to 0 °C. A 
saturated solution of HCl/Et2O was added and the reaction mixture was allowed to stir at 
room temperature overnight. The precipitate was collected by filtration to yield a pale 
yellow solid, which upon recrystallization from acetone afforded 0.012 g (13%) of 90 as an 
off-white solid: mp 265-270 °C (lit.171 270-274 °C, MeOH/Et2O) 1H (DMSO-d6): 1.39-
1.58 (m, 2H, CH2), 1.79-1.97 (m, 2H, CH2), 2.03 (s, 3H, OCH3), 2.70-2.76 (m, 1H, CH), 
3.17-3.24 (m, 1H, CH2), 3.65-3.67 (m, 1H, CH2), 3.88-3.91 (m, 1H, CH2), 4.41-4.44 (m, 
1H, CH2), 6.84 -6.86 (m, 1H, ArH), 7.01-7.03 (m, 1H, ArH), 7.26 (s, 1H, ArH), 9.20 (br s, 
1H, NH+).  
 
3-[2-[4-(6-Fluoro[1H]indol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- 
4H-pyrido[1,2-a]pyrimidin-4-one hydrochloride (91). 
In a 2-neck flask, 3-(2-chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-
a]pyrimidin-4-one (92) (0.20 g, 0.88 mmol) and compound 89 (0.19 g, 0.88 mmol) were 
added to a stirred solution of K2CO3 (0.12 g, 0.882 mmol) and KI (few crystals) in 
anhydrous MeCN (18 mL) under an N2 atmosphere. The stirred reaction mixture was 
heated at reflux for 45 h, cooled to room temperature and the solvent was evaporated under 
reduced pressure. The residue was suspended in H2O and extracted with CHCl3 (3 x 50 
    
 151 
mL). The combined organic portion was washed with H2O (3 x 50 mL), dried (Na2SO4) 
and evaporated under reduced pressure to yield a yellow-colored solid. The solid was 
dissolved in anhydrous Et2O (2 mL) and cooled to 0 °C. A saturated solution of gaseous 
HCl in Et2O (2 mL) was added and the reaction mixture was allowed to stir at room 
temperature overnight. The precipitate was collected by filtration to yield a yellow-colored 
solid, which upon recrystallization from EtOH/H2O afforded 0.05 g (37%) of 91 as a 
yellow solid: mp 279-281 °C. 1H (DMSO-d6): 1.62-1.68 (m, 2H, CH2), 1.68-1.79 (m, 2H, 
CH2), 1.83-1.94 (m, 4H, CH2), 2.11-2.16 (m, 2H, CH2), 2.21(s, 3H, CH2), 2.36-2.40 (m, 
2H, CH2), 2.59-2.63 (m, 2H, CH2), 2.74-2.78 (m, 3H, CH2), 3.01-3.04 (m, 2H, CH2), 3.77-
3.80 (t, J = 4 Hz, 2H, CH2), 6.78-6.84 (m, 1H, ArH), 7.08-7.11(m, 2H, ArH), 7.51-7.54 
(dd, J = 4 Hz, 1H, ArH), 10.37 (br, s, 1H, NH+, D2O ex), 10.98 (s, 1H, NH, D2O ex) Anal. 
Calcd. for (C24H29N4OF·2HCl·0.5H2O) C, 58.77; H, 6.57; N, 11.42 Found: C, 58.78; H, 
6.61; N, 11.22. 
 
3-(2-(1-Piperidinyl)ethyl)-2,4(1H,3H)-quinazolinedione hydrochloride (94). 
Compound 95 (0.10 g, 0.54 mmol) was added to piperidine (68) (3 mL) and the stirred 
reaction mixture was heated at reflux for 4 h. The excess piperidine was removed under 
reduced pressure to yield a tan-colored solid. The solid was dissolved in anhydrous Et2O (5 
mL) and cooled to 0 °C. A saturated solution of gaseous HCl in Et2O (2 mL) was added 
and the reaction mixture was allowed to stir at room temperature overnight. The precipitate 
was collected by filtration to yield a white solid that was recrystallized from absolute 
EtOH to yield 0.06 g (75%) of 94 as a white solid: mp 274-276 °C (lit.143 276-278 °C). 1H 
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NMR (DMSO-d6): 1.38-1.44 (m, 1H, CH2), 1.62-1.85 (m, 3H, CH2), 1.82-1.85 (m, 2H, 
CH2), 2.90-2.98 (m, 2H, CH2), 3.34-3.35 (m, 2H, CH2), 3.62-3.65 (m, 2H, CH2), 4.25- 4.28 
(m, 2H, CH2), 7.22-7.26 (m, 2H, ArH), 7.68-7.72 (t, J = 8 Hz, 1H, ArH), 7.95-7.97 (d, J = 
8 Hz, 1H, ArH), 9.38 (br s, 1H, NH+, D2O ex), 11.60 (s, 1H, NH+, D2O ex). 
 
2,3-Dihydro-5H-oxazolo[2,3-b]quinazolin-5-one (95). 
3-(2-Chloroethyl)-2,4(1H,3H)quinazolinedione (93) (0.30 g, 1.33 mmol) was added to a 
stirred solution of K2CO3 (0.18 g, 1.33 mmol) in anhydrous acetone (9 mL). The stirred 
reaction mixture was heated at reflux for 2 h, cooled to room temperature and evaporated 
under reduced pressure. The residue was suspended in H2O and extracted with CH2Cl2 (3 x 
10 mL). The combined organic portion was washed with H2O (3 x 10 mL), dried (Na2SO4) 
and evaporated to dryness under reduced pressure to yield 0.19 g (77 %) of 95 as a white 
solid: mp 159-162 °C (lit.143 160-162 °C), which was used without further purification in 
the preparation of compounds 85 and 94. 
 
1-Acetylpiperidine-4-carboxylic acid (97). 
A stirred solution of isonipecotic acid (75) (8.0 g, 61.93 mmol) and EtOAc (24 mL) was 
cooled to 0 °C (ice-bath). Then Ac2O (8.7 mL, 92.89 mmol) was added and the reaction 
mixture was allowed to stir at 5 °C for 0.16 h. The stirred reaction solution was heated at 
60 °C for 2 h and cooled to room temperature. The precipitate was collected by filtration, 
washed with diisopropyl ether to yield 10.2 g of 97 (96%) as a white solid: mp 182-184 °C 
(lit.171 180-182 °C), which was used crude in the preparation of compound 98.  
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1-Acetylpiperidine-4-carboxylic acid chloride (98). 
In a 3-neck flask, SOCl2 (61 mL, 6.37 mmol) was added to a stirred solution of 97 (10.0 g, 
58.41 mmol) in ClCH2CH2Cl (24 mL) under an N2 atmosphere and the reaction mixture 
was allowed to stir at room temperature for 6 h. The precipitate was collected by filtration 
to yield 10.50 g of 98 (95%) as a white solid: mp 138-140 °C (lit.171 133-138 °C), which 
was used crude in the preparation of compound 99.  
 
1-Acetyl-4-(2-hydroxy-5-methoxybenzoyl)piperidine (99). 
In a 3-neck flask, AlCl3 (14.06 g, 105.46 mmol) was added to a stirred solution of 
compound 98 (1.00 g, 52.73 mmol), 1,3-dimethoxybenzene (7.28 g, 52.73 mmol) and 
ClCH2CH2Cl (5 mL) under an N2 atmosphere and the reaction mixture was heated at reflux 
for 45 h. The reaction mixture was cooled to room temperature, quenched by the careful 
addition of ice/H2O (50 mL) and the aqueous portion was extracted with CHCl3 (3 x 50 
mL). The combined organic portion was washed with H2O (3 x 50 mL), brine (5 mL), 
dried (Na2SO4), and evaporated under reduced pressure to yield a pale yellow-colored oil 
which, when triturated with petroleum ether, afforded a pale yellow solid, which upon 
recrystallization with EtOH yielded 0.20 g (13%) of 99 as a yellow solid: mp 93-95 °C 
(lit.171 93-94 °C).  
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1-Acetyl-4-((2-hydroxy-5-methoxyphenyl)(hydroxyimino)methyl)piperidine (100). 
In a 3-neck flask, 99 (0.20 g, 3.61 mmol) was added to a stirred solution of hydroxylamine 
hydrochloride (0.29 g, 4.26 mmol) in EtOH (16 mL) under an N2 atmosphere. A solution 
of NH4OAc (0.61 g, 7.94 mmol) in H2O (4.80 mL) was added and the reaction mixture 
was heated at reflux for 36 h. The reaction mixture was allowed to cool to room 
temperature and filtered. The filtrate was evaporated under reduced pressure to yield a 
yellow-colored solid that was recrystallized from H2O to yield 0.12 g of 100 (54%) as a 
yellow solid: mp 196-200 °C (lit.171 193-196 °C), which was converted to the acetate salt: 
mp 208-210, and used crude in the preparation of compound 101. 
 
1-Acetyl-4-(5-methoxybenz[d]isoxazol-3-yl)piperidine (101). 
Toluene-washed NaH (0.011 g, 0.463 mmol) was added to a stirred solution of the acetate 
salt of compound 100 (0.15 g, 0.42 mmol) in anhydrous DMF (2 mL) and the stirred 
reaction mixture was heated at reflux for 6 h. The reaction mixture was allowed to stir at 
room temperature for 24 h, quenched by pouring in H2O (25 mL) and the reaction mixture 
was extracted with EtOAc (3 x 20 mL). The combined organic portion was washed with 
H2O (3 x 20 mL), brine (5 mL), dried (Na2SO4), and evaporated under reduced pressure to 
yield 0.09 g of 101 (81%) as a brown oil, which was verified spectrally and used crude in 
the preparation of compound 90.  
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B. Molecular modeling studies: 
The primary sequence of the human 5-HT2A receptor was obtained from the Universal 
Protein Resource (UniProt) (entry code: P28223; Homo sapiens) in the FASTA format. 
The amino acid sequence of the crystal structure of the 5-HT2B receptor (PDB ID: 4IB4) 
was retrieved from the Protein Data Base (PDB). During crystallization, residues Y249-
V313 (ICL3) of the 5-HT2B receptor were replaced with A1-L106 of BRIL.187,206 These 
residues were deleted\ from the amino acid sequence file of the crytal structure of the          
5-HT2B receptor prior to sequence alignment. Multiple sequence alignment of the 5-HT2B 
receptor amino acid sequence with the 5-HT2A receptor sequence was performed with the 
software ClustalX2.0, which provided output in the form of .ps, .aln and .dnd files. One 
hundred homology models of the 5-HT2A receptor were generated using the software 
package Modeller 9.12207 (version 9.12; University of California San Francisco, San 
Francisco, CA). Modeller processes the sequence alignment in the form of the .ali format, 
which, along with the sequence alignment also includes details about the template, and the 
protein of interest.  
 
The model for comparing the binding pocket of the receptor to previously published 5-
HT2A homology models was chosen based on the discrete optimized protein energy 
(DOPE) scores and the models were further examined by docking studies of ketanserin.  
 
The ligands were built using the sketch feature within SYBYL-X 2.1 (Tripos International, 
St. Louis, MO, USA), and were energetically minimized using the Tripos Force Field 
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[Gasteiger-Hückel charges, the dielectric constant (ε) = 4, the non bonded interaction 
cutoff = 8 Å and was terminated at an energy gradient of 0.05 kcal/(mol*Å)] feature within 
SYBYL-X 2.1. 
 
Molecular docking was performed using the GOLD scoring function within the genetic 
algorithm docking program GOLD208 (Version 5.3; Cambridge Crystallographic Data 
Centre, Cambridge, UK). The binding pocket was defined to include all atoms within 10-Å 
of the α-carbon atom of the highly conserved D155 (TM3). The docking solutions were 
sorted by cluster docking (the script was provided by Dr. Philip D. Mosier) and examined 
on SYBYL-X 2.1) The models chosen (based on binding interactions and their GOLD 
scores) were merged with the ligands and energetically minimized using the Tripos Force 
Field (Gasteiger Hückel charges, distance-dependent dielectric constant = 4.0). The models 
were further evaluated by HINT analysis194 (as implemented within SYBYL 8.1) to 
quantify the ligand-receptor interactions and the model with the highest HINT scores was 
chosen for every ligand under the study. PyMOL was used to generate images.209 
 
C. Functional activity studies: 
a. Calcium imaging epifluorescence assay:  
Measurements of Intracellular Ca2+ 
Cells (HEK293 cells) were plated on 96-well dishes the day before the experiment. The 
next day cells were switched to serum-free medium for about 3-4 hours, before being 
loaded with 5 µm Fura2-AM (Molecular Probes, OR) in Imaging Solution (125 mM NaCl, 
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5 mM KCl, 2 mM CaCl2, 1 mM MgSO4, 6 mM glucose, and 25 mM Hepes/Tris, pH 7.4). 
Following incubation for 30 min at 37oC, cells were washed with imaging solution and 
kept at room temperature for about 15 min before being placed on the stage of an 
epifluorescence microscope, coupled to an automatic perfusion system. 
 
The Fura-2 signal was acquired at 510 nm by switching the excitation wavelength between 
340 nm and 380 nm. Intracellular calcium concentration was expressed as a 340/380 nm 
ratio and values were normalized to the basal 340/380 nm ratio level before perfusion of 
the drug. Results were expressed as mean ± SEM. Statistical significance was determined 
by two-tailed Student’s t test. IC50 values are obtained by analysis in GraphPad PRISM 
(version 6.00 for Mac OS X, GraphPad Software, La Jolla California, US).210  
 
b. Electrophysiology studies:  
The electrophysiological functional assay studies were conducted in the Xenopus laevis 
heterologous oocyte system expressing the 5-HT2A and the GIRK4* channels. After they 
were enzymatically isolated, the oocytes were microinjected with 1-2 ng cRNA constructs. 
The oocytes were then incubated for 2 days at 18 °C for expression. Responses were 
recorded by conventional two-electrode voltage clamp (TEVC) assay with a 
GeneClamp500 amplifier (Axon Instruments) 3-5 days after cRNA injection. A high 
potassium concentration solution containing 96 KCl, 1NaCl, MgCl2, 5 KOH/HEPES, in 
mM) was used to record basal channel expression levels and a 3mM BaCl2 was used to 
block the GIRK4* currents.173 
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D. Radioligand binding studies: 
The radioligand binding studies were performed in HEK293 cells transiently transfected 
with the N-terminally c-Myc-tagged form of wild type human 5-HT2A receptor 
(pcDNA3.1-c-Myc-5HT2A) using Lipofectamine 2000 reagent (Invitrogen). The cell 
pellets were homogenized using a Teflon-glass grinder (10 up-and-down strokes at 1500 
rpm) after 48 hours in 1 mL of binding buffer (50 mM Tris-HCl, pH 7.4), supplemented 
with 0.25 M sucrose. The crude homogenate was centrifuged at 1000 g for 5 min at 4 °C, 
and the supernatant was centrifuged at 40,000 g for 15 min at 4 °C. The resultant pellet (P2 
fraction) was washed twice in homogenization buffer and re-centrifuged in similar 
conditions. Aliquots were stored at 80 °C until assay. Curves were carried out by 
incubating each drug (10-10–10-4 M; 13 concentrations) in binding buffer containing 2 nM 
[3H]-ketanserin. Nonspecific binding was determined in the presence of 10 µM 
methylsergide (Tocris). Competition curves were analyzed by nonlinear regression by 
GraphPad PRISM (version 6.00 for Mac OS X, GraphPad Software, La Jolla California, 
US) to derive dissociation constants for high (Ki-high) and low (Ki-low) affinity states of the 
receptor211 that were reported only as a single Ki value in Tables/Figures. The equation for 
the curve fitting: log EC50 = log (10^log Ki*(1 + Radioligand NM/HotKd NM)  
Y = Bottom + (Top - Bottom)/(1 + 10 ^ (X-logEC50)). 
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Appendix A 
 
 
 
 
After the dissertation had been written, additional data on the activity of risperidone and 
compounds 56 and 57 at the GIRK4* channel in the presence and the absence of the          
5-HT2A receptor in the TEVC assay system were obtained.  
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Figure A1. Inhibitory action of risperidone (3) at the GIRK4* channel in the presence and 
the absence of the 5-HT2A receptor in the TEVC assay. (N = 4/condition). Data are mean ± 
SEM, *p < 0.05, experiments were replicated in a second batch of oocytes.  
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Figure A2. Inhibitory action of compound 56 at the GIRK4* channel in the presence and 
the absence of the 5-HT2A receptor in the TEVC assay. (N = 4/condition). Data are mean ± 
SEM, *p < 0.05, experiments were replicated in a second batch of oocytes.  
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Figure A3. Inhibitory action of compound 57 at the GIRK4* channel in the presence and 
the absence of the 5-HT2A receptor in the TEVC assay. (N = 4/condition). Data are mean ± 
SEM, *p < 0.05, experiments were replicated in a second batch of oocytes.  
 
Risperidone (3) was tested at concentrations of 30, 50 and 100 µM (Figure A1), compound 
56 was studied at 30 and 50 µM (Figure A2), and compound 57 was tested at 5, 10, 30 and 
50 µM (Figure A3). All three compounds showed comparable agonist activity at the 
GIRK4* channel in the presence and absence of the 5-HT2A receptor. This suggests that 
the positive efficacy shown by compounds 56 and 57 in the TEVC assay (Figure 27A) 
could be due to their activity at the GIRK4* channel instead of Gαq-mediated activity at the 
5-HT2A receptor.  
 
The activity seen with compound 57 at 50 µM in Figure 27B was comparable to its activity 
at GIRK4* in the absence of the 5-HT2A receptor when studied at 50 µM (Figure A3). The 
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above information coupled with the high binding affinity of compound 57 at the receptor 
(Figure 30 and Table 4) imply that compound 57 might not be a superagonist or an ago-
allosteric modulator as speculated earlier, and that the 5-HT- potentiating activity seen at 
the concentration of 50 µM (Figure 27B) could be solely due to its activity at the GIRK4* 
channel. As a consequence, the IC50 values shown in Table 4 for the TEVC assay might 
not be valid.  
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